

- 1 -

MEGASTOKES AMINO-TRIAZOLYL-BODIPY COMPOUNDS AND
APPLICATIONS TO LIVE NEURON STAINING AND HUMAN SERUM
ALBUMIN FA1 DRUG SITE PROBING

RELATED APPLICATION

5 This application claims the benefit of U.S. Provisional Application No. 61/745,916, filed on December 26, 2012.

 The entire teachings of the above application are incorporated herein by reference.

BACKGROUND OF THE INVENTION

10 The need for understanding essential recognition events in chemistry and biology has directed considerable efforts toward the development of chemical probes. Fluorescent probes are attractive and versatile tools for both analytical sensing and optical imaging because of their high sensitivity, fast response time, and technical simplicity. However, the mechanisms that regulate the interaction between fluorescent
15 probes and their targets are often poorly understood; hence, the ability to predict structural requirements and to design new probes using theoretical calculations is limited. Combinatorial approaches have recently boosted the generation and optimization of fluorescent probes, especially for complex scientific problems that remain indefinite at the molecular recognition level. The development of combinatorial
20 strategies for derivatizing known fluorescent scaffolds with commercially available building blocks using conventional synthetic procedures would enable access to a broader scope of fluorescent probes.

 The development of fluorescent and molecular imaging probes based on the BODIPY scaffold has been widely exploited due to its outstanding fluorescent
25 properties (e.g. high photostability, extinction coefficients and quantum yields, tunable excitation and emission spectra) (1-7) and facile conversion into probes for Positron Emission Tomography (PET) imaging (8,9). Most methods to derivatize the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) scaffold involve solution-phase

chemistry, which often requires tedious purification steps (10). Efforts to derivatize BODIPY on-solid-phase have been hampered by its lability in both acidic and basic conditions (11).

There is a need to develop methods to rapidly achieve new compound libraries based on useful fluorescent scaffolds, such as the BODIPY-based scaffold. Moreover, within these libraries, there is a need to develop selective and specific probes for various analytes with critical biological functions.

SUMMARY OF THE INVENTION

The present invention is based the discovery of selective fluorescent probes for detection of biological analyte human serum albumin, and the related discovery of fluorescent probes that are selective for the visualization of live neurons. Accordingly, in one embodiment, the invention is a novel class of amino-triazolyl BODIPY compounds. The compounds of the present invention are rapidly synthesized through high-throughput synthetic methods and contain three moieties that may be derivatized. The present invention also relates to methods of synthesis of the amino-triazolyl BODIPY compounds. Specifically, both solid-phase and solution-phase synthetic methods are described. In another embodiment, the present invention is a fluorescent probe for human serum albumin. In yet another embodiment, the invention is a fluorescent dye for selective staining of primary neurons. The present invention further relates to methods for the detection of human serum albumin in a sample of biological fluid. In some embodiments, the measure of fluorescence intensity is proportional to the concentration of human serum albumin. Also described herein are methods for visualizing live neurons, which may be used in *in vitro* or *in vivo* applications.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings.

FIG. 1 shows the BODIPY-based BDC and MK library designs, and also points out the relationships between structure and spectral properties.

FIG. 2 shows normalized absorbance and fluorescence emission spectra of representative amino-triazolyl-BODIPYs. BDC-8 (*Blue*): absorbance $\lambda_{\max} = 473$ nm,

emission $\lambda_{\max} = 585$ nm; MK101-8 (*Green*): absorbance $\lambda_{\max} = 474$ nm, emission $\lambda_{\max} = 563$ nm; MKHA374-48 (*Yellow*): absorbance $\lambda_{\max} = 468$ nm, $\lambda_{\text{em}} = 557$ nm. The corresponding spectra of a reported BODIPY (BD-27; *Red*) are also included for comparison: absorbance $\lambda_{\max} = 551$ nm, emission $\lambda_{\max} = 568$ nm. The structures of BDC-8, MK101-8, MKHA374-48 and BD-27 are also depicted.

FIG. 3 shows the effect of solvent viscosity on the fluorescence intensity of BDC-9 (100 μM) at rt. Intensity of BDC-9 systematically increased in more viscous alcohols when in *n*-octanol and *n*-hexanol.

FIG. 4 shows the fluorescence response (F) of BDC-9 (10 μM) toward different proteins at various concentrations (0.13, 0.25, 0.50, 1.00 mg/mL) in 10 mM HEPES buffer (pH 7.4); $\lambda_{\text{exc.}}$: 460 nm, $\lambda_{\text{em.}}$: 575 nm). F_0 is the fluorescence intensity of BDC-9 in HEPES buffer. Values are represented as means ($n = 4$).

FIG. 5 shows the fluorescence spectra of BDC-9 (10 μM) upon incubation with serial dilutions of HSA (from 1.2×10^{-4} to 4 mg/mL) in phosphate buffer, $\lambda_{\text{exc.}}$: 460 nm. Values are represented as means ($n = 3$).

FIG. 6 shows the fluorescence emission response of BDC-9 (10 μM) upon incubation with serial dilutions of HSA; $\lambda_{\text{exc.}}$: 460 nm, $\lambda_{\text{em.}}$: 575 nm; values are represented as means and error bars as standard deviations ($n = 3$); LOD = 0.3 $\mu\text{g/mL}$; linear range = 0.37 to 31 $\mu\text{g/mL}$, $R^2 = 0.999$.

FIGs. 7a and 7b show species selectivity of BDC-9. Specifically, FIG. 7a shows fluorescence emission response of BDC-9 (10 μM) upon interaction with serial dilutions of the respective albumins (from 1.2×10^{-4} to 4 mg/mL); $\lambda_{\text{exc.}}$: 460 nm, $\lambda_{\text{em.}}$: 575 nm; values are represented as means and error bars as standard deviations ($n = 3$). FIG. 7b is a photographic image of BDC-9 (10 μM) mixed with respective albumins. Irradiation with a handheld UV lamp at 365 nm.

FIG. 8 shows competition with site-selective HSA-binding drugs. HSA (fatty-acid free) (0.34 mg/mL, 5 μM) was preincubated for 2 h in phosphate buffer with different concentrations of the drugs (up to 200 μM) before BDC-9 (10 μM) was added. F is the fluorescence intensity at the indicated drug concentration and F_0 is the fluorescence intensity with no drug added; $\lambda_{\text{exc.}}$: 460 nm, $\lambda_{\text{em.}}$: 575 nm; values are represented as means and error bars as standard deviations ($n = 3$).

FIG. 9 shows a job plot analysis. Specifically, BDC-9 was mixed with HSA (fatty-acid-free) at different ratios in phosphate buffer while maintaining total concentration at 20 μ M; λ_{exc} : 460 nm, λ_{em} : 575 nm; values are represented as means and error bars as standard deviations ($n = 3$).

5 FIG. 10 is a fluorescence spectrum showing fluorescence emission of serial dilutions of BDC-9 (0, 0.47 to 60 μ M) upon incubation with HSA (10 μ M) in phosphate buffer; λ_{exc} : 460 nm, λ_{em} : 575 nm; values are represented as means and error bars as standard deviations ($n = 3$); $K_D = 12.7 \pm 0.4$ μ M (one-site specific binding model).

10 FIG. 11 shows the fluorescence response of BDC-9 in urine samples. HSA (0 to 1 mg/mL) was added to 10% urine from healthy individuals in phosphate buffer (pH = 7.3). BDC-9 was added at 10 μ M concentration; λ_{exc} : 460 nm, λ_{em} : 575 nm; values represented as means ($n = 3$) and error bars as standard deviations; linear regression: $R^2 = 0.998$.

15 FIG. 12a shows flow cytometry profiles of MKCA101-3 (*left*), MKHA101-3 (*middle*) and MKAA101-3 (*right*) stained mixed primary neural cell populations showing the neuronal population segregating from the main population based on compound fluorescence (~2G up to ~3.5G). Unstained controls are shown in each spectrum from about 0 to about 1G.

20 FIG. 12b images of neurons derived from differentiated neurospheres. MKHA101-3 shows significantly improved specificity over MKCA101-3.

FIG. 13 shows chemical structures of MKHA101-3 and its derivatives.

FIG. 14 shows chemical structures of MKHA374-48 affinity analogues.

25 FIG. 15 shows a schematic of primary neural screening for the identification of the neuron specific probe, MKHA101-3. The image on the left shows brightly stained neurons as opposed to their other glial cell counterparts.

FIG. 16a shows the structures of MKHA101-3 (left) and MKHA374-48 / NeuO (right).

30 FIG. 16b is flow cytometry profiles of MKHA101-3 (left) and NeuO (right) stained with mixed live neuron cell populations showing the neuronal population segregating from the main population based on compound fluorescence

FIG. 17 shows live cell confocal images of MKHA101-3 stained neurons at 100X magnification, scale bar 20 μ m and live cell compound staining and

immunostaining of mixed primary neural cell cultures. Cells were stained with 500nM of MKHA101-3 (Green) and imaged at 10X magnification before fixing with 4% PFA. They were then permeabilized with 0.1% Triton-X and immunostained with GFAP (Red) and neurons (Green).

5 FIG. 18 shows live cell compound staining and immunostaining of mixed primary neural cell cultures. Cells were stained with 500nM of NeuO (*Green*) and imaged at 10X magnification before fixing with 4% PFA. They were then permeabilized with 0.1% Triton-X and immunostained with β -III-tubulin (Tuji, Yellow), GFAP (Red) and O4).

10 FIG. 19a shows a flow cytometry scatter profile of mixed primary neural cells from the mouse neonate and adult brain stained with 500 nM of NeuO.

FIG. 19b is a bar graph showing gene expression of β -III-tubulin as measured from cells sorted from whole (unsorted), bright and dim fractions of neonate and adult brains.

15 FIG. 19c shows a flow cytometry scatter profile of mixed primary neural cells stained with 500 nM of MKHA101-3. The histogram on the right shows that compound positive cells make up 20% of the whole cell population.

FIG. 20a shows live cells with a neuronal morphology recultured from the compound positive fraction.

20 FIGs. 20b and 20c show immunostained cells found to be positive for β -III-tubulin (Green), nuclei staining (Blue); Scale bar: 50 μ m.

FIG. 21 is a bar graph showing the expression of β -III-tubulin in the whole (unsorted), bright and dim fractions of MKHA101-3 stained mixed primary neural cells. The bright fraction clearly shows a higher expression of β -III-tubulin compared to the whole and dim fractions.

25

FIG. 22 is a bar graph demonstrating neuron viability. Primary neurons were isolated from P1-3 mouse pups by preferential adherence to poly-D-lysine coating. They were left to mature for 5 days before addition of compound at the stipulated concentrations for 24h. The MTS assay (Promega) was used to assess viability according to manufacturer's instructions.

30

FIG. 23, in the upper panel, shows video stills of DIV1 neuron cultures, stained with 500nM NeuO and imaged using time lapse imaging to visualize neuron dendrite

formation. The lower panel of FIG. 23 shows time lapse imaging of neuronal development/ differentiation from neural progenitors. Bright NeuO-stained neurons can be seen migrating from the interior of the sphere.

FIG. 24 depicts affinity molecules designed for covalent binding to neuronal targets and affinity enrichment.

FIG. 25 depicts a representative scheme for using AffiNeuO7 and AffiNeuO5 series for affinity enrichment.

FIG. 26 depicts NeuO-PETs, which may be used in some embodiments for PET imaging.

FIG. 27 depict NeuR and NeuIR red fluorescent probes for live neurons.

FIG. 28 shows Embryo brain slices stained with MKHA101-3 and imaged at 10X magnification. Images captured shows that the dyes specifically highlighted cells with long dendritic processes which are reminiscent of neuronal staining.

DETAILED DESCRIPTION OF THE INVENTION

A description of example embodiments of the invention follows.

A novel class of triazole-derivatized 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) compounds is disclosed. This class of compounds includes two novel fluorescent probes, including a human serum albumin (HSA) probe that is the first to independently bind to fatty acid site 1, and also including a neuronal cell probe that stains specifically and uniquely primary neurons.

Library Design – MegaStokes Amino-Triazolyl-BODIPY Compounds

The first solid-phase BODIPY library employing Knoevenagel reactions and mildly acidic cleavage conditions that preserved the integrity of the fluorophore was recently reported (12). The present invention relates to an alternative solid-phase combinatorial derivatization strategy employing Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) to prepare the first library of amino-triazolyl-BODIPY compounds (BDC and MK) and their corresponding acetyl (AC), chloroacetyl (CA) and hydroxyacetyl (HA) derivatives (13). Notably, the introduction of a triazole moiety paired with an amino substituent at the positions 3 and 5 of the BODIPY core rendered fluorescent compounds with very large Stokes shifts (from 74 to 160 nm). MegaStokes dyes, which minimize the overlap between their excitation and emission spectra, offer

an increased sensitivity over other fluorophores and an exceptional potential as sensors for *in-vitro* applications. While other fluorescent structures (e.g. coumarin, styryl) have been modified to increase their Stokes shifts, compounds of the BDC and MK libraries disclosed herein represent the first systematic generation of MegaStokes dyes based on the BODIPY scaffold. Furthermore, these amino-triazolyl-BODIPY compounds displayed sensitivity to environmental changes. Identified herein are compounds that behave as environmentally-sensitive fluorescent turn-on sensors. The inherent fluorescence of such BODIPY core structures is recovered at specific environments.

Design, Synthesis and Photophysical Properties


CuAAC is highly favored for combinatorial purposes due to its high efficiency, robustness and its success with mild reaction conditions (13,14). The resulting triazole ring is chemically stable and, at certain positions within a fluorescent core, can modulate the spectral wavelengths of the resulting fluorescent derivatives (15,16). A survey of the literature revealed that the incorporation of electron-donating and withdrawing groups at positions 3 and 5 of the BODIPY scaffold can effectively alter its Stokes shifts (17-19). Based on these reports, a trifunctional BODIPY aniline (4, Scheme 1) was designed for the synthesis of the BODIPY library. This scaffold possesses three points for diversification – two electrophilic sites at positions 3 and 5, which can be modified, for example, via CuAAC and nucleophilic substitution respectively (20-24), and one aniline site at the meso position, which can be modified by acetylation.

Two methods for synthesizing Amino-Triazolyl BODIPY compounds were developed, namely, the solid-phase method and the solution phase method. The solution-phase method allows for production of the BODIPY compound on a larger scale, while the solid-phase method provides a practical route to large library of compounds. Both methods are detailed below.

Solid-Phase Synthesis

The solid-phase method allows for the rapid synthesis of a large library of Amino-Triazolyl BODIPY compounds on small scale. The aniline function on 4 enabled loading of the scaffold onto chlorotriyl chloride polystyrene (CTC-PS) resin. Subsequent cleavage under weakly acidic conditions preserves the integrity of the fluorophore (Scheme 1) (12). In certain embodiments, other chlorinated or brominated solid support scaffolds may be used.

In an example embodiment, the synthesis of **4** consisted of four steps with an overall yield of 37%. **1** was readily prepared from *p*-nitrobenzaldehyde and pyrrole following reported methods (25,26). Chlorination with *N*-chlorosuccinimide (NCS) followed by oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) afforded **2**, which was subsequently treated with $\text{BF}_3 \cdot \text{OEt}_2$ to obtain the highly stable BODIPY analogue **3** (26,27). Reduction with activated iron rendered **4** in quantitative yields. The aniline was then loaded onto CTC-PS resin using standard coupling conditions. Treatment with sodium azide generated a di-substituted azide intermediate upon which diversity was introduced, first by mono-substitution with the amine building blocks (Scheme 3) and subsequently by the CuAAC with the alkyne building blocks (Scheme 4). Final cleavage with 0.5% trifluoroacetic acid (TFA) in CH_2Cl_2 yielded the corresponding amino-triazolyl-BODIPY compounds of the BDC and MK libraries with average purities of 95% in minimum purification steps. These compounds possess a free aniline which can be further acetylated with acid chloride building blocks for added functionality, generating corresponding acetyl (AC), chloroacetyl (CA), acetoxycetyl (AA) and hydroxyacetyl (HA) derivatives (Scheme 5). In certain embodiments, a CA tag is useful for protein labeling, while a HA tag coupled to some MK compounds possess a specific fluorescence response to primary neurons. In certain embodiments, an AA tag, and other similar derivatives, can be a useful hydrophobic HA precursor with improved permeability into intact live cells. Subsequent hydrolysis by cellular esterases liberates the active HA compound.


Scheme 1. Solid-Phase Synthesis of Amino-Triazolyl BODIPY Compounds.

Reagents and conditions: (a) pyrrole, TFA, rt, 3 h; (b) NCS, dry THF, -78°C to rt, 3 h; (c) DDQ, dry CH_2Cl_2 , rt, 1 h; (d) BF_3OEt_2 , dry CH_2Cl_2 , rt, 2 h; (e) activated Fe, $\text{CH}_3\text{OH}:\text{CH}_3\text{COOH}$ (10:1), reflux, 15 min; (f) CTC-PS resin, DIEA, $\text{CH}_2\text{Cl}_2/\text{DMF}$, rt,

24 h; (g) NaN₃, DMF, rt, 30 min; (h) DMF:piperidine (4:1), rt, 45 min; (i) DMF:R²R³NH (4:1), rt, 1 h; (j) R¹-C≡CH, CuI, ascorbic acid, rt, 30 min; (k) 0.5% TFA in CH₂Cl₂; (l) R⁴COCl, sat. NaHCO₃, rt, 10 min; (m) CH₃COOCH₂COCl, sat. NaHCO₃, rt, 10 min; (n) K₂CO₃, MeOH, H₂O, rt, 1 h. The dark sphere in compound **5** represents chlorotrityl polystyrene resin.

Solution Phase Synthesis

In alternate embodiments, a solution phase method to generate the BDC and MK compounds is used for large-scale synthesis of the dyes (Scheme 2). In an example embodiment, compounds **1**, **2** and **3** were synthesized as described in the solid-phase method. The amino and triazolyl functions were subsequently added to **3**. Compound **3** was first treated with approximately 2.2 equivalents of sodium azide in dimethylformamide (DMF) solvent to generate a di-substituted azide intermediate. This was immediately followed by nucleophilic substitution with 1 equivalent of the respective amine building block (Scheme 3) without purification. Upon reaction completion, the DMF was removed, and the crude mixture re-dissolved in *tert*-butanol solvent before performing CuAAC with the appropriate alkyne building block (Scheme 4). Final reduction of the nitrobenzene moiety with activated iron revealed the corresponding BDC and MK compounds, which are optionally further acetylated using the steps described in solid-phase synthesis to generate corresponding acetyl (AC), chloroacetyl (CA), acetoxycetyl (AA) and hydroxyacetyl (HA) derivatives (Scheme 5).

Scheme 2. Solution Phase Synthesis of Amino-Triazolyl BODIPY Compounds.


Reagents and conditions: (a) pyrrole, TFA, rt, 3 h; (b) NCS, dry THF, -78°C to rt, 3 h; (c) DDQ, dry CH₂Cl₂, rt, 1 h; (d) BF₃OEt₂, dry CH₂Cl₂, rt, 2 h; (e) NaN₃ (2.2 equiv.) DMF, rt, 30 min; (f) piperidine (1 equiv.), DMF, rt; (g) R²R³NH (1 equiv), DMF, rt, 1 h;

(h) $R^1-C\equiv CH$, CuI, ascorbic acid, *t*BuOH, rt; (i) activated Fe, $CH_3OH:CH_3COOH$ (10:1), reflux; (j) R^4COCl , sat. $NaHCO_3$, rt, 10 min; (k) CH_3COOCH_2COCl , sat. $NaHCO_3$, rt, 10 min; (l) K_2CO_3 , MeOH, H_2O , rt, 1 h.


In certain embodiments, the amine building blocks of the present invention include primary and secondary amines, for example HNR_xR_y , wherein R_x and R_y are each independently H, $(C_1-C_{10})alkyl$, $(C_6-C_{10})aryl(C_0-C_6)alkyl$, $(C_3-C_{10})heteroaryl$, $(C_3-C_8)cycloalkyl$, $(C_2-C_{10})alkynyl$ or $(C_2-C_{10})alkenyl$, each of which is optionally substituted with 1-5 substituents, each at any position, and each selected from $(C_1-C_6)alkyl$, $(C_1-C_6)alkoxy$, NH_2 , $-NH(C_1-C_6 alkyl)$, $-NH(CO)(C_1-C_6 alkyl)$, $-NH(CO)(C_1-C_6 haloalkyl)$, $-NH(CO)(C_1-C_6 alkoxy)$, $-NH(CO)(C_1-C_6 haloalkoxy)$, $-NH(CO)(C_2-C_6 alkenyl)$, $-Si(C_1-C_6 alkyl)$, $-SO_2(C_1-C_6 alkyl)$, $-SH$, $-B(OH)_2$, $-OTosyl$, $-CO(C_1-C_6 alkoxy)$, $-COH$, $-COOH$, $-CO(C_1-C_6 alkyl)$ or halogen. In preferred embodiments, the substituent does not have a hydroxyl group present. In alternate embodiments, the R_x and R_y substituents may be taken together to form a ring, such that the ring comprises a cyclic amino group such as piperidine and pyrrolidine, and may include heteroatoms such as in morpholine. The cyclic amino group is optionally substituted by 1-5 substituents selected from halogen or $(C_1-C_6)alkyl$, or is optionally fused together with another ring system, for example an aromatic ring system. The substitution can be present at any of the ortho, meta, or para positions of an aromatic ring system. In certain other embodiments, the amine building block includes a benzyl amine, which is optionally substituted at any one or more positions by a substituent, each independently selected from H, $(C_1-C_6)alkyl$, $(C_1-C_6)alkoxy$, NH_2 , $-NH(C_1-C_6 alkyl)$, $-NH(CO)(C_1-C_6 alkyl)$, $-NH(CO)(C_1-C_6 haloalkyl)$, $-NH(CO)(C_1-C_6 alkoxy)$, $-NH(CO)(C_1-C_6 haloalkoxy)$, $-NH(CO)(C_2-C_6 alkenyl)$, $-Si(C_1-C_6 alkyl)$, $-SO_2(C_1-C_6 alkyl)$, $-SH$, $-B(OH)_2$, $-OTosyl$, $-CO(C_1-C_6 alkoxy)$, $-COH$, $-COOH$, $-CO(C_1-C_6 alkyl)$ or halogen. In alternate embodiments, the amine building block is amino benzene, wherein the benzene ring is optionally substituted at any one or more positions by a substituent, each independently selected from H, $(C_1-C_6)alkyl$, $(C_1-C_6)alkoxy$, NH_2 , $-NH(C_1-C_6 alkyl)$, $-NH(CO)(C_1-C_6 alkyl)$, $-NH(CO)(C_1-C_6 haloalkyl)$, $-NH(CO)(C_1-C_6 alkoxy)$, $-NH(CO)(C_1-C_6 haloalkoxy)$, $-NH(CO)(C_2-C_6 alkenyl)$, $-Si(C_1-C_6 alkyl)$, $-SO_2(C_1-C_6 alkyl)$, $-SH$, $-B(OH)_2$, $-OTosyl$, $-CO(C_1-C_6 alkoxy)$, $-COH$, $-COOH$, $-CO(C_1-C_6 alkyl)$


or halogen. Certain example embodiments of amine building blocks that may be used in the invention are shown in Scheme 3.

Scheme 3. Amine Building blocks for the BDC and MK libraries.



In certain embodiments of the invention, the alkyne building block is a compound of the formula $R^1-C\equiv CH$, where R^1 is selected from (C_1-C_{10}) alkyl, (C_3-C_8) cycloalkyl, (C_6-C_{10}) aryl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, or (C_3-C_{10}) heteroaryl, further wherein R^1 is optionally substituted at any position with 1-5 substituents selected from (C_1-C_{10}) alkyl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, (C_3-C_8) cycloalkyl, (C_1-C_6) alkoxy, (C_6-C_{10}) aryloxy, (C_6-C_{10}) aryl, amino, $-NH(CO)(C_1-C_6)$ alkyl, $-NH(CO)(C_2-C_6)$ alkenyl, $-NH(CO)(C_2-C_6)$ alkynyl, $-NH(CO)(C_1-C_6)$ haloalkyl, halo, OCF_3 , CF_3 , hydroxyl, or a halogen radioisotope. Certain example embodiments of alkyne building blocks that may be used in the present invention are shown in Scheme 4.

Scheme 4. Alkyne building blocks for the BDC and MK libraries.

Scheme 5. Derivatives of the Aniline Moiety

In certain embodiments of the invention, the acid chloride building block has the structure of the formula $R^4\text{COCl}$, wherein R^4 is $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$, which is optionally substituted with 1-3 additional substituents at any position, the substituents independently selected from halogen, hydroxyl, -NH_2 , NH-acetyl , or O-acetyl . Preferred embodiments of acid chloride include the following substitutions. When R^4 is methyl, an AC derivative is formed (*e.g.*, BDCAC or MKAC). When R^4 is CH_2Cl , a CA derivative is formed. Similarly, when R^4 is CH_2X , an XA derivative is formed. AA derivatives include compounds in which R^4 is CH_2OAc , and HA derivatives include R^4 equal to CH_2OH .

Photophysical Properties

Many of the amino-triazolyl-BODIPY compounds of the present invention exhibited similar absorbance wavelength maxima (Table 1), whereas their emission maxima spanned across a much broader range. Notably, the spectral properties of MegaStokes BODIPY dyes can be fine-tuned with different alkyne building blocks. In some embodiments, electron-rich alkynes (*e.g.* 4-ethynyl-*N,N*-dimethylaniline) generate compounds with longer absorption wavelengths than alkynes containing electron-withdrawing groups (*e.g.* 4-(trifluoromethoxy)phenylacetylene). While BDC and MK compounds exhibited low quantum yields due to photoinduced electron transfer (PeT) effect (28,29), the acetylation of the aniline group partially recovered their fluorescence emission with an average 7-fold fluorescence increase. On the other hand, MK compounds derived from primary amine building blocks displayed an additional 4 to 7-fold increase in fluorescence quantum yields. Without being bound to theory, it is

believed that this phenomenon is a result of an intramolecular hydrogen bond formed between the free NH and BODIPY-fluorine, which reduces the conformational flexibility of structure and hence, increases fluorescence (30). These properties affirm the ability of the BDC and MK compounds of the present invention to behave as fluorescent turn-on sensors with potentially tunable quantum yields.

Table 1. Spectral properties of amino-triazolyl-BODIPY compounds.

Library	λ_{abs} range / nm	λ_{em} range / nm	Average Quantum Yield (ϕ)
BDC	466 – 478	547 – 616	0.002
BDCAC	459 – 469	537 – 619	0.014
BDCCA	458 – 468	537 – 627	0.012
MK	470 – 481	560 – 596	1° amines: 0.012 2° amines: 0.003
MKAC	461 – 470	558 – 590	1° amines: 0.19 2° amines: 0.026
MKCA	459 – 470	558 – 587	1° amines: 0.29 2° amines: 0.040
MKHA/MKAA	468 – 470	556 – 560	0.31

Amino-Triazolyl BODIPY compounds as Fluorescent Molecular Rotors

The Amino-triazolyl BODIPY compounds of the present invention have freely rotatable motifs at positions 3 and 5 of the BODIPY core. In certain embodiments, specific environments restrict the rotation of these motifs. These environments include interacting with a suitable analyte. Restriction of the rotation results in a turn-on fluorescence response. The molecular rotor characteristics of the amino-triazolyl BODIPY compounds are validated in Example 2, via fluorescence analysis of the spectra of BDC-9 in different solvents of similar polarities, which cover a range of viscosities.


A Unique Probe for Human Serum Albumin

Human serum albumin (HSA) is the most abundant protein in the human blood plasma. With a circulating concentration of about 0.6 mM, HSA plays a major role in

maintaining osmotic pressure and physiological pH (31). Albuminuria – the loss of HSA in urine – is a well-established cardiovascular risk marker and an indication of liver and renal disease (32,33). More importantly, this incredibly plastic protein is the major transporter for a wide array of essential ligands including hormones, fatty acids and drug molecules. Consequently, efforts have been made to develop sensitive and site specific fluorescent probes that can be used for detecting and quantifying HSA in biofluids and identifying binding sites of drugs.

HSA consists of nine binding sites (34-38), amongst which fatty acid (FA) sites 1, 3 and 4 (Sudlow Site II), 5, 6 and 7 (Sudlow Site I) are known to have affinity for drug compounds (31,39-44). Therefore, there is great need to designing fluorescent probes applicable for simple competition assays to identify drug binding sites. Probes have successfully been developed for FA sites 3, 4, 6 and 7 (45-61). However, fluorescent probes for the remaining sites are lacking. The different sites of HSA have different physical properties and have important roles in the pharmacokinetics of drugs. Therefore, identifying the HSA binding site or sites of drugs is crucial. Fluorescent compounds that bind specifically to the different HSA sites can be a convenient tool for probing the binding site of drugs using simple competition assays. There is a need to develop selective fluorescent probes with a binding affinity for fatty acid 1 or 5 of HSA.

The amino-triazolyl-BODIPY compounds of the present invention are especially useful as fluorescent probes for biological analytes such as human serum albumin. Specifically, compounds of Formula (I) exhibit selectivity for HSA, wherein Formula (I) is:



wherein:


R^1 is H or $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$, wherein $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or -NH_2 ;

R^2 and R^3 are each, independently, H, $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_0\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$ or $(\text{C}_2\text{-C}_{10})\text{alkenyl}$, wherein R^2 and R^3 are optionally substituted at any position with 1-5 substituents selected from $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, NH_2 , $\text{-NH}(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkoxy})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkoxy})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkenyl})$, $\text{-Si}(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-SO}_2(\text{C}_1\text{-C}_6\text{ alkyl})$, -SH , $\text{-B}(\text{OH})_2$, -OTosyl , $\text{-CO}(\text{C}_1\text{-C}_6\text{ alkoxy})$, -COH , -COOH , $\text{-CO}(\text{C}_1\text{-C}_6\text{ alkyl})$ or halogen;

or R^2 and R^3 are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or $(\text{C}_1\text{-C}_6)\text{alkyl}$; and

R^4 is $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, $(\text{C}_2\text{-C}_{10})\text{alkenyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$, or $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkenyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, $(\text{C}_6\text{-C}_{10})\text{aryloxy}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, amino, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkenyl})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkynyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkyl})$, halo, OCF_3 , CF_3 , hydroxyl, or a halogen radioisotope.

In more particular embodiments, the compound of Formula (II) is selective for the FA1 site of HSA:



In certain embodiments, the invention is a fluorescent probe for human serum albumin (HSA), comprising a compound of Formula (II).

In other embodiments, the invention is a method for detecting human serum albumin (HSA) in a sample of a biological fluid, comprising contacting a sample of

biological fluid thought to contain HSA with a compound of Formula (I) to form an incubation media;

incubating the incubation media under conditions sufficient to form an incubated mixture; and

- 5 analyzing the mixture of by fluorescence microscopy, wherein an increase in the fluorescence signal of the mixture relative to the fluorescence signal of the compound of Formula (I) not in the presence of a sample containing HSA is indicative of the presence of HSA.

In some embodiments of the method to detect HSA, a measure of intensity of the
10 fluorescence signal is proportional to the concentration of the HSA present in the sample. In certain embodiments, the compound of Formula (I) has the structure of Formula (II). "Incubating", as used herein, can mean mixing, either by mechanical means, or else by diffusion. Incubating can further comprise maintaining a temperature profile. In certain embodiments, a compound of Formula (I) has a baseline
15 fluorescence. Therefore, in an analytical method to determine the presence of HSA, a change in fluorescence, for example an increase in fluorescence signal or a shift in emission maxima, relative to the baseline fluorescence of Formula (I), is indicative of the target analyte. Methods of visualizing a live neuron include fluorescence microscopy. Fluorescence microscopy methods for measuring a fluorescence signal of a
20 compound of Formula (I) include general fluorescence microscopy, confocal, two-photon, and superresolution (e.g. STORM) microscopy.

X-ray crystallographic studies of HSA have found that the FA1 site is an important drug binding site. Compared to existing fluorescent probes, the amino-triazolyl BODIPY compounds of the present invention can be used for the direct
25 probing of drugs that bind to the HSA FA1 site using simple binding competition assays. Upon binding to HSA, the fluorescent dye exhibits very high fluorescence. Drugs having an affinity to the FA1 site compete with the fluorescent dye for site binding. Hence, in another embodiment of the invention, the present invention includes a method for assessing drug binding to the FA1 site of HSA, the methods comprising
30 monitoring the decrease in dye fluorescence. The methods also provide a measure of the drug's binding strength.

A Unique Probe for Primary Neurons


Elucidating the complex neuronal networks that govern neural function have long been a subject of interest to neuroscientists who believed that human thought could be deciphered by mapping the tangle of neuron connections within the brain (82). As
5 such numerous neuron labeling methods have also evolved to enable the visualization of these complex cells. These include the Golgi method, Nissl staining as well as calcium dyes such as Fura and Dil (83). However, most established neuron labeling dyes work best on fixed tissue preparations or are not selective for neurons but rather depend on retrograde labeling or manual injection to achieve the desired effect in live cells (84).
10 Apart from those mentioned above, there are no chemical dyes to date that are capable of specifically labeling live neurons in their *in vitro* or *in vivo* settings.

The availability of a neuron compound negates the need for antibody and transgenic animal use. This is especially useful in the case of neurons because most neuronal markers are intracellular (e.g. β -III-tubulin, MAP2, NeuN) and hence require
15 cell permeabilization (and hence cell death). A wide range of fluorescent protein expressing neuron mouse models are available, however the expression of fluorescent proteins is not consistent throughout animal development (e.g. time needed for activation of cre-recombinase in the Thy1 transgenic mouse line) (85). Thus there are windows of neuronal development which are still difficult to study, with each possibly
20 requiring different neuronal models for the best fluorescent protein expression. Also, incorporation of fluorescent protein expression may possibly interfere with cell function thus making it difficult to draw functional conclusions from these transgenic models (86).

The absence of good neuronal markers for cell isolation is also an issue (87).
25 Neurons are generally difficult to isolate and culture. They are most viable and open to *in vitro* culture at embryonic and post-natal stages, likely due to increased plasticity at an early developmental stage although it has been established that adult neurons too can be isolated for *in vitro* culture given the appropriate culture and isolation conditions (88). The use of lentiviral transfection has also become a popular method for selectively
30 labeling neuronal populations of interest (89). Current methods of neuron labeling involved antibody labeling, which compromises the viability of the cells or transgenic modification for fluorescent protein expression, which may affect the native function of

the cells. A majority of neuron labeling dyes that are on the market lack neuronal specificity but rather rely on retrograde labeling or microinjection to achieve neuron labeling. However, these methods are time consuming and often suffer from low labeling efficiency. There remains a need for a fluorescent dye that is able to label live neurons, enabling a wide range of cell tracking and isolation applications without the restrictions imposed by some of the previously mentioned methodologies.

The amino-triazolyl-BODIPY compounds of the present invention are especially useful as fluorescent probes for primary neurons. The compounds disclosed herein achieve live neuron specific labeling over other neural cells. This can be applied generically to all neuronal cell preparations regardless of genetic background and results in a stable fluorescent signal which is useful for many applications. Specifically, compounds of Formula (I) exhibit selectivity for staining live neurons, wherein Formula (I) is:



wherein:


R^1 is H or $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$, wherein $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or -NH_2 ;

R^2 and R^3 are each, independently, H, $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_0\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$ or $(\text{C}_2\text{-C}_{10})\text{alkenyl}$, wherein R^2 and R^3 are optionally substituted at any position with 1-5 substituents selected from $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, NH_2 , $\text{-NH}(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkoxy})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkoxy})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkenyl})$, $\text{-Si}(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-SO}_2(\text{C}_1\text{-C}_6\text{ alkyl})$, -SH , $\text{-B}(\text{OH})_2$, -OTosyl , $\text{-CO}(\text{C}_1\text{-C}_6\text{ alkoxy})$, -COH , -COOH , $\text{-CO}(\text{C}_1\text{-C}_6\text{ alkyl})$ or halogen;

or R^2 and R^3 are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or (C_1-C_6) alkyl; and

R^4 is (C_1-C_{10}) alkyl, (C_3-C_8) cycloalkyl, (C_6-C_{10}) aryl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, or (C_3-C_{10}) heteroaryl, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from (C_1-C_{10}) alkyl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, (C_3-C_8) cycloalkyl, (C_1-C_6) alkoxy, (C_6-C_{10}) aryloxy, (C_6-C_{10}) aryl, amino, $-NH(CO)(C_1-C_6)$ alkyl, $-NH(CO)(C_2-C_6)$ alkenyl, $-NH(CO)(C_2-C_6)$ alkynyl, $-NH(CO)(C_1-C_6)$ haloalkyl, halo, OCF_3 , CF_3 , hydroxyl, or a halogen radioisotope.


In more particular embodiments, the compound of Formula (III) is selective for staining live neurons:



wherein:

R^2 , R^3 , and R^4 are defined as in Formula (I).


In other particular embodiments, the compound of Formula (XIV) is selective for staining live neurons:



wherein:


- R^4 is (C_1-C_{10}) alkyl, (C_3-C_8) cycloalkyl, (C_6-C_{10}) aryl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, or (C_3-C_{10}) heteroaryl, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from (C_1-C_{10}) alkyl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, (C_3-C_8) cycloalkyl, (C_1-C_6) alkoxy, (C_6-C_{10}) aryloxy, (C_6-C_{10}) aryl, amino, -NH(CO) (C_1-C_6) alkyl, -NH(CO) (C_2-C_6) alkenyl, -NH(CO) (C_2-C_6) alkynyl, -NH(CO) (C_1-C_6) haloalkyl, halo, OCF₃, CF₃, hydroxyl, or a halogen radioisotope; and
- R^5 is present at any position with 1-5 substituents selected from H, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, NH₂, -NH (C_1-C_6) alkyl, -NH(CO) (C_1-C_6) alkyl, -NH(CO) (C_1-C_6) haloalkyl, -NH(CO) (C_1-C_6) alkoxy, -NH(CO) (C_1-C_6) haloalkoxy, -NH(CO) (C_2-C_6) alkenyl, -Si (C_1-C_6) alkyl, -SO₂ (C_1-C_6) alkyl, -SH, -B(OH)₂, -OTosyl, -CO (C_1-C_6) alkoxyl, -COH, -COOH, -CO (C_1-C_6) alkyl or halogen.

In yet another particular embodiment, the selective stain for live neurons is a compound of Formula (V):



15

In some embodiments, the invention is a fluorescent dye for the specific staining of live neurons. In certain embodiments, the dye is a compound of formula (XV):



wherein:

R^2 and R^3 are each, independently, H, (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₁₀)heteroaryl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl or (C₂-C₁₀)alkenyl;

5 wherein (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl and (C₂-C₁₀)alkenyl are optionally substituted at any position with 1-5 substituents selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, NH₂, -NH(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ haloalkyl), -NH(CO)(C₁-C₆ alkoxy), -NH(CO)(C₁-C₆ haloalkoxy), -NH(CO)(C₂-C₆ alkenyl), -Si(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SH, -B(OH)₂, -OTosyl, -CO(C₁-C₆ alkoxy), -COH, -COOH, -CO(C₁-C₆ alkyl) or halogen;

or R^2 and R^3 are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or (C₁-C₆)alkyl;

R^6 is H or CO(CH₃); and

15 R^7 is (C₁-C₁₀)alkyl, (C₃-C₈)cycloalkyl, (C₆-C₁₀)aryl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, or (C₃-C₁₀)heteroaryl, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₃-C₈)cycloalkyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, (C₆-C₁₀)aryl, amino, -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₂-C₆ alkenyl), -NH(CO)(C₂-C₆ alkynyl), -NH(CO)(C₁-C₆ haloalkyl), halo, OCF₃, CF₃, hydroxyl, or a halogen radioisotope.

20 In other embodiments, the invention is a method for visualizing live neurons in a cell culture, comprising: contacting a cell culture with a compound of Formula (I) to form an incubation media, incubating the incubation media of under conditions sufficient to stain the live neurons and visualizing the stained live neurons with
25 fluorescence microscopy.

In certain embodiments, the method utilizes a compound of Formula (I) having the structure of Formula (XIV) or (V). In certain embodiments, the method is used in an *in vitro* application. In certain other embodiments, the method is used in an *in vivo* application. "Incubating", as used herein, can mean mixing, either by mechanical means, or else by diffusion. Incubating can further comprise maintaining a temperature profile. Methods of visualizing a live neuron include fluorescence microscopy. In certain other embodiments, for example for compounds containing ^{18}F , positron Emission Tomography (PET) techniques may be used. Fluorescence microscopy includes general fluorescence microscopy, confocal, two-photon, and superresolution (e.g. STORM) microscopy.

In certain embodiments, the neuron dyes of the present invention monitor neuron viability, development and dendrite formation in *in vitro* cultures/assays of neural cells. The dyes disclosed herein can also be combined with other fluorescent cell labels to investigate cellular interactions. The dyes may also be applied to brain slices and *in vivo* for neuron imaging by two photon or whole animal imaging. Neuron dyes may have applications in disease models such as Rett or Parkinson's, where they can be used to monitor the degeneration of neurons in disease pathogenesis.

DEFINITIONS

"Alkyl" means a saturated aliphatic branched or straight-chain monovalent hydrocarbon radicals, typically $\text{C}_1\text{-C}_{10}$, preferably $\text{C}_1\text{-C}_6$. " $(\text{C}_1\text{-C}_6)$ alkyl" means a radical having from 1- 6 carbon atoms in a linear or branched arrangement. " $(\text{C}_1\text{-C}_6)$ alkyl" includes methyl, ethyl, propyl, butyl, *tert*-butyl, pentyl and hexyl.

"Alkylene" means a saturated aliphatic straight-chain divalent hydrocarbon radical. Thus, " $(\text{C}_1\text{-C}_6)$ alkylene" means a divalent saturated aliphatic radical having from 1- 6 carbon atoms in a linear arrangement. " $(\text{C}_1\text{-C}_6)$ alkylene" includes methylene, ethylene, propylene, butylene, pentylene and hexylene.

"Heterocycle" means a saturated or partially unsaturated (3-7 membered) monocyclic heterocyclic ring containing one nitrogen atom and optionally 1 additional heteroatom independently selected from N, O or S. When one heteroatom is S, it can be optionally mono- or di-oxygenated (*i.e.*, $-\text{S}(\text{O})-$ or $-\text{S}(\text{O})_2-$). Examples of monocyclic heterocycle include, but not limited to, azetidine, pyrrolidine, piperidine, piperazine,

hexahydropyrimidine, tetrahydrofuran, tetrahydropyran, morpholine, thiomorpholine, thiomorpholine 1,1-dioxide, tetrahydro-2H-1,2-thiazine, tetrahydro-2H-1,2-thiazine 1,1-dioxide, isothiazolidine, or isothiazolidine 1,1-dioxide.

“Cycloalkyl” means saturated aliphatic cyclic hydrocarbon ring. Thus,

- 5 “C₃-C₈ cycloalkyl” means (3-8 membered) saturated aliphatic cyclic hydrocarbon ring. C₃-C₈ cycloalkyl includes, but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Preferably, cycloalkyl is C₁-C₆ cycloalkyl.

- The term “alkoxy” means -O-alkyl; “hydroxyalkyl” means alkyl substituted with hydroxy; “aralkyl” means alkyl substituted with an aryl group; “alkoxyalkyl” mean
10 alkyl substituted with an alkoxy group; “alkylamine” means amine substituted with an alkyl group; “cycloalkylalkyl” means alkyl substituted with cycloalkyl; “dialkylamine” means amine substituted with two alkyl groups; “alkylcarbonyl” means -C(O)-A*, wherein A* is alkyl; “alkoxycarbonyl” means -C(O)-OA*, wherein A* is alkyl; and where alkyl is as defined above. Alkoxy is preferably O(C₁-C₆)alkyl and includes
15 methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.

“Cycloalkoxy” means an cycloalkyl-O- group wherein the cycloalkyl is as defined above. Exemplary (C₃-C₇)cycloalkyloxy groups include cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy and cycloheptoxy.

- “Hetero” refers to the replacement of at least one carbon atom member in a ring
20 system with at least one heteroatom selected from N, S, and O. A hetero ring system may have 1 or 2 carbon atom members replaced by a heteroatom.

“Halogen” and “halo” are interchangeably used herein and each refers to fluorine, chlorine, bromine, or iodine.

“Cyano” means -C≡N.

- 25 “Nitro” means -NO₂.

- As used herein, an amino group may be a primary (-NH₂), secondary (-NHR_x), or tertiary (-NR_xR_y), wherein R_x and R_y may be any alkyl, aryl, heterocyclyl, cycloalkyl or alkenylene, each optionally and independently substituted with one or more substituents described above. The R_x and R_y substituents may be taken together to form
30 a “ring”, wherein the “ring”, as used herein, is cyclic amino groups such as piperidine and pyrrolidine, and may include heteroatoms such as in morpholine.

The terms "haloalkyl", "halocycloalkyl" and "haloalkoxy" mean alkyl, cycloalkyl, or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br or I. Preferably the halogen in a haloalkyl or haloalkoxy is F.

5 The term "acyl group" means $-C(O)B^*$, wherein B^* is an optionally substituted alkyl group or aryl group (e.g., optionally substituted phenyl).

An "alkylene group" is represented by $-[CH_2]_z-$, wherein z is a positive integer, preferably from one to eight, more preferably from one to four.

10 An "alkenylene group" is an alkylene in which at least a pair of adjacent methylenes are replaced with $-CH=CH-$.

15 The term "(C₆-C₁₆)aryl" used alone or as part of a larger moiety as in "arylalkyl", "arylalkoxy", "aryloxy", or "aryloxyalkyl", means carbocyclic aromatic rings. The term "carbocyclic aromatic group" may be used interchangeably with the terms "aryl", "aryl ring", "carbocyclic aromatic ring", "aryl group" and "carbocyclic aromatic group". An aryl group typically has 6-16 ring atoms. A "substituted aryl group" is substituted at any one or more substitutable ring atom. The term "C₆-C₁₆ aryl" as used herein means a monocyclic, bicyclic or tricyclic carbocyclic ring system containing from 6 to 16 carbon atoms and includes phenyl (Ph), naphthyl, anthracenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl and the
20 like. The (C₆-C₁₀)aryl(C₁-C₆)alkyl group connects to the rest of the molecule through the (C₁-C₆)alkyl portion of the (C₆-C₁₀)aryl(C₁-C₆)alkyl group.

The term benzyl (Bn) refers to $-CH_2Ph$.

25 The term "heteroaryl", "heteroaromatic", "heteroaryl ring", "heteroaryl group" and "heteroaromatic group", used alone or as part of a larger moiety as in "heteroarylalkyl" or "heteroarylalkoxy", refers to aromatic ring groups having five to fourteen total ring atoms selected from carbon and at least one (typically 1 - 4, more typically 1 or 2) heteroatoms (e.g., oxygen, nitrogen or sulfur). They include monocyclic rings and polycyclic rings in which a monocyclic heteroaromatic ring is fused to one or more other carbocyclic aromatic or heteroaromatic rings. The term "5-
30 14 membered heteroaryl" as used herein means a monocyclic, bicyclic or tricyclic ring system containing one or two aromatic rings and from 5 to 14 total atoms of which, unless otherwise specified, one, two, three, four or five are heteroatoms independently

selected from N, NH, N(C₁₋₆alkyl), O and S. (C₃-C₁₀)heteroaryl includes furyl, thiophenyl, pyridinyl, pyrrolyl, imidazolyl, and in preferred embodiments of the invention, heteroaryl is (C₃-C₁₀)heteroaryl.

The term "2-4 member polycyclyl" is a cyclic compound with 2-4 hydrocarbon
5 loop or ring structures (*e.g.*, benzene rings). The term generally includes all polycyclic aromatic compounds, including the polycyclic aromatic hydrocarbons, the heterocyclic aromatic compounds containing sulfur, nitrogen, oxygen, or another non-carbon atoms, and substituted derivatives of these.

The term "Alkenyl" means a straight or branched hydrocarbon radical including
10 at least one double bond. The (C₆-C₁₀)aryl(C₂-C₆)alkenyl group connects to the remainder of the molecule through the (C₂-C₆)alkenyl portion of (C₆-C₁₀)aryl(C₂-C₆)alkenyl. Similarly, the term "alkynyl" means a straight or branched hydrocarbon radical including at least one carbon-carbon triple bond.

Pharmaceutically acceptable salts of the compounds of the present invention are
15 also included. For example, an acid salt of a compound of the present invention containing an amine or other basic group can be obtained by reacting the compound with a suitable organic or inorganic acid, resulting in pharmaceutically acceptable anionic salt forms. Examples of anionic salts include the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate,
20 chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylsarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate,
25 succinate, sulfate, tannate, tartrate, teoclate, tosylate, and triethiodide salts.

Salts of the compounds of the present invention containing a carboxylic acid or
other acidic functional group can be prepared by reacting with a suitable base. Such a pharmaceutically acceptable salt may be made with a base which affords a
pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium
30 and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine,

piperidine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acids such as lysine and arginine.

A solid support resin is used in solid phase synthesis. One such example is a "CT-PS resin". Specifically, it is 2-chlorotrityl-polystyrene.

A "cellular extract" is lysed cells from which insoluble matter has been removed via centrifugation.

A "tissue section" is a portion of tissue suitable for analysis. A tissue section can refer to a single tissue section or a plurality of tissue sections.

A "biological fluid" is a liquid or gas of biological origin. In the present application, a biological fluid can include blood, blood plasma, urine, saliva, and mucous.

As used herein, "spectroscopy" encompasses any method by which matter reacts with radiated energy. This includes, but is in no way limited to, microscopy, fluorescence microscopy, UV/Vis spectrometry, and flow cytometry.

As used herein, a "chemical reactive moiety" refers to a low molecular weight, nonprotein compound that can be incorporated into a structure or compound, such as a fluorophore, that is useful for detection of a biological analyte. In preferred embodiments of the invention, the chemical reactive moiety is covalently bound to the fluorophore, either through an atom in its own structure, or a covalently bound chemical linking group. A key feature of a chemical reactive moiety for use with the present invention is its ability to bind a biological analyte. In a preferred embodiment, a chemical reactive moiety is selective for binding a certain biological analyte. Examples of such chemical reactive moieties include acryloyl groups, haloacetyl groups, N-hydroxy succinimide esters, imidoesters, pentafluorophenyl esters, hydroxymethyl phosphines, maleimides, pyridyldisulfides, thiosulfonates, vinylsulfones, hydrazides, alkoxyamines, aryl azides, benzophenones, and isocyanates. In preferred embodiments, the chemical reactive moiety is biotin, which binds avidin for detection, or a diazirine moiety, which works as a photoreactive crosslinker. Illumination by UV light (360 nm)

generates a carbene from the diazirine which then reacts to form covalent bonds with nearby nucleophiles present in the biological analyte.

EXAMPLES

5 Example 1. Synthesis of BDC and MK BODIPY Compounds.

Materials

All commercially available reagents, solvents and proteins were purchased from Sigma Aldrich, Alfa Aesar, Fluka, Merck or Acros, and used as received unless otherwise stated. CH₂Cl₂ (Fisher Scientific, analytical grade) was freshly distilled from P₂O₅ under nitrogen. Anhydrous THF was purchased from Alfa Aesar and used without
10 further purification. Phosphate buffer was prepared following a modified recipe of Dulbecco's PBS buffer (1x): 0.2 g KH₂PO₄, 2.17 g Na₂HPO₄•7H₂O, 1000 mL MilliQ™ H₂O, pH 7.3.

Analysis

15 ¹H-NMR, ¹⁹F-NMR and ¹³C-NMR spectra were recorded on Bruker ACF300 (300 MHz), DPX300 (300 MHz) and AMX500 (500 MHz) spectrometers. High resolution mass spectra (ESI) were obtained on a Finnigan/MAT 95XL-T spectrometer. Spectroscopic and quantum yield data were measured on a SpectraMax M2 spectrophotometer (Molecular Devices). Data analysis was performed using GraphPrism
20 5.0. Analytical characterization was performed on a HPLC-MS (Agilent-1200 series) with a DAD detector and a single quadrupole mass spectrometer (6130 series) with an ESI probe. Analytical HPLC method: eluents, A: H₂O (0.1% HCOOH), B: CH₃CN (0.1% HCOOH), gradient 5% B to 95% B (10 min). Reverse-phase Phenomenex C₁₈ Luna column (4.6 x 50 mm², 3.5 μm particle size), flow rate: 1 mL/min.

25 *Quantum yield measurements*

Quantum yields were calculated by measuring the integrated emission area of the fluorescent spectra and comparing to the area measured for Acridine Yellow in EtOH when excited at 460 nm ($\Phi_{\text{AcridineYellow fluorescence}} = 0.47$). Quantum yields for the amino-triazolyl-BODIPYs were calculated using the equation below, where F represents the area of
30 fluorescent emission, η is the refractive index of the solvent, and Abs is absorbance at

the excitation wavelength selected for standards and samples. Emission was integrated between 510 and 700 nm.

$$\Phi_{\text{fluorescence}}^{\text{sample}} = \Phi_{\text{fluorescence}}^{\text{reference}} \left(\frac{F^{\text{sample}}}{F^{\text{reference}}} \right) \left(\frac{\eta^{\text{sample}}}{\eta^{\text{reference}}} \right) \left(\frac{Abs^{\text{reference}}}{Abs^{\text{sample}}} \right)$$

5 Synthesis

General procedure for the preparation of BDC and MK library compounds on solid phase:

2-chlorotrityl chloride resin (220 mg, 0.275 mmol) was swollen in CH₂Cl₂ (3.0 mL) for 15 min. A solution of **4** (30 mg, 0.085 mmol) and DIEA (200 µL, 1.15 mmol) in 10 DMF:CH₂Cl₂ (1:1, 2 mL) was added to the resin suspension and shaken at rt for 24 h, after which the resin was capped with MeOH (0.4 mL, 1.8 mL/g resin) and DIEA (100 µL) for 12 h. The resin was filtered, washed with DMF (4 × 10 mL) and CH₂Cl₂ (4 × 10 mL) and dried. The loaded resin was resuspended in CH₂Cl₂ and shaken at rt for 15 minutes and washed with DMF. A suspension of NaN₃ (50 mg, 0.77 mmol) in DMF 15 (3.0 mL) was added and the reaction mixture further shaken at rt for 30 min. After washing with DMF (4 × 10 mL), a solution of DMF:piperidine (4:1) (4.0 mL) was added and the reaction was shaken for 45 minutes. The alkyne (0.854 mmol), CuI (65 mg, 0.34 mmol) and ascorbic acid (60 mg, 34 mmol) were subsequently added and the reaction mixture shaken for another 30 min. The resin was filtered, washed with DMF 20 (4 × 10 mL) and CH₂Cl₂ (4 × 10 mL), following which cleavage was performed with 0.5% TFA in CH₂Cl₂ (3 × 15 mL, 10 min each). The organic extracts were recovered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (eluent: CH₂Cl₂ to CH₂Cl₂:MeOH (98:2) to afford the corresponding BDC and MK library compound as an orange solid (generally ca. 16 mg, 0.03 mmol, 70% 25 yield). Tables 2 and 5 have specific chemical structures and detailed characterization data, including percent purity at 254 nm, calculated and experimentally determined mass, λ_{max} for the absorption and emission spectra, and quantum yield (φ).

General procedure for the preparation of BDC and MK library compounds in solution phase:

30 To a solution of **3** (100 mg, 0.26 mmol) in acetonitrile (1 mL) was added NaN₃ (34 mg, 0.52 mmol) and stirred for 30 min. The corresponding amine (0.26 mmol) was

then added and the reaction stirred for an additional 1 h. The reaction mixture was evaporated *in vacuo* and re-dissolved in *t*-BuOH:THF:H₂O (4:1:1) (1 mL), following which the alkyne (0.26 mmol), CuI (50 mg, 0.26 mmol) and ascorbic acid (46 mg, 0.26 mmol) were added and stirred for 30 min. Organic solvents were evaporated *in vacuo* and the resulting residue diluted with water (20 mL) and extracted with DCM (20 mL x 3). The combined organic extracts were concentrated *in vacuo* and purified by flash column chromatography on silica gel. The resulting residue was dissolved in EtOH (1 mL) and acetic acid (0.1 mL) and heated to 90°C. A suspension of iron powder (28 mg, 0.5 mmol) was activated in 1M HCl for 1 min, rinsed with absolute EtOH and added to the reaction mixture. Upon reaction completion, iron was removed and the solvent was evaporated *in vacuo*. The residue was diluted with CH₂Cl₂ (20 mL) and washed with saturated NaHCO₃ (3 x 20 mL). The organic extract was washed with saturated brine and dried over anhydrous Na₂SO₄ and evaporated *in vacuo* to afford the corresponding BDC and MK library compound as an orange solid (generally ca. 35 mg, 0.06 mmol, 24% overall yield). Tables 2 and 5 have specific chemical structures and detailed characterization data.

General procedure for the preparation of BDCAC, BDCCA, MKAC and MKCA library compounds:

To a solution of the respective BDC and MK compounds (generally ca. 6 mg, 0.011 mmol) in CH₂Cl₂ (1.5 mL), 6 drops of saturated aqueous NaHCO₃ were added and cooled to 0°C. An acid chloride (generally ~10 µL, 0.11 mmol) was added in portions over 1 min and the resulting mixture was stirred at rt and monitored by analytical TLC. Upon reaction completion, the reaction was diluted with CH₂Cl₂ (15 mL), washed with water (2 x 15 mL), saturated NaHCO₃ (1 x 15 mL), saturated brine (1 x 15 mL) and dried over anhydrous Na₂SO₄. The organic extract was evaporated to afford the corresponding BDCAC, BDCCA, BDCXA, MKAC, MKCA or MKXA compounds as an orange solid (generally ca. 6 mg, > 90% yield). Tables 3, 4, 6 and 7 have specific chemical structures and detailed characterization data.

General procedure for the preparation of MKHA compounds:

To a solution of the respective MK compound (generally ca. 6 mg, 0.011 mmol) in CH₂Cl₂ (1.5 mL), 6 drops of saturated aqueous NaHCO₃ were added and cooled to 0°C. Acetoxylacetyl chloride (10 µL, 0.11 mmol) was added in portions over 1 min and

the resulting mixture was stirred at rt and monitored by analytical TLC. Upon completion, CH_2Cl_2 was evaporated and the mixture re-dissolved in MeOH (1.5 mL). 6 drops of saturated aqueous Na_2CO_3 were added and the reaction mixture stirred at rt and monitored by analytical TLC. The reaction was diluted with CH_2Cl_2 (15 mL), washed with water (2×15 mL), saturated NaHCO_3 (1×15 mL), saturated brine (1×15 mL) and dried over anhydrous Na_2SO_4 . The organic extract was evaporated to afford the corresponding MKHA compound as an orange solid (generally ca. 6 mg, > 90% yield). Table 8 contains chemical structures and detailed characterization data.

Preparation procedures for specific compounds and characterization data:

10 2,2'-((4-nitrophenyl)methylene)bis(1H-pyrrole) (**1**). To a solution of 4-nitrobenzaldehyde (1.0 g, 6.6 mmol) in pyrrole (10 mL, 144 mmol) was added TFA (0.51 mL, 0.66 mmol) and stirred at rt for 3 h. The mixture was concentrated *in vacuo*, and purified by flash column chromatography on silica gel (hexane: EtOAc, 4:1) to afford **1** as a bright yellow solid (1.63 g, 6.10 mmol, 92 % yield). ^1H NMR (300 MHz, CDCl_3): δ 8.17 (d, $J = 8.7$ Hz, 2H), 7.99 (br. s, 2H), 7.36 (d, $J = 8.7$ Hz, 2H), 7.99 (br. s, 2H), 6.75 (d, $J = 5.8$ Hz, 2H), 6.18 (dd, $J = 5.8, 2.9$ Hz, 2H), 5.87 (br. s, 2H), 5.58 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 144.7, 144.2, 132.2, 130.5, 123.8, 118.0, 108.5, 107.7, 45.9$; MS (ESI): m/z $[\text{M}+\text{H}]^+ = 268.1$.

1,1'-Dichloro-5-(4-nitrophenyl)dipyrromethene (**2**). A solution of **1** (1.1 g, 4.1 mmol) in anhydrous THF (35 mL) was stirred under N_2 atmosphere at -78°C for 15 min. *N*-chlorosuccinimide (1.4 g, 10.3 mmol) in anhydrous THF (35 mL) was added dropwise using a pressure equalizing funnel and the resulting mixture was stirred at rt for 3 h. Upon completion, 2,3-dichloro-5,6-dicyano-*p*-benzoquinone (1.12 g, 4.92 mmol) was added and the reaction mixture stirred at rt for an additional 2 h. THF was removed *in vacuo* and the resulting mixture was diluted with water (20 mL) and extracted with CH_2Cl_2 (3×70 mL). The combined organic extracts were washed with saturated brine, dried over anhydrous Na_2SO_4 and the solvents removed *in vacuo*. The resulting residue was purified by flash column chromatography on silica gel (hexane: EtOAc, 10:1) to afford **2** as a dark orange solid (0.78 g, 2.3 mmol, 57% yield). ^1H NMR (300 MHz, CDCl_3): $\delta = 8.32$ (d, $J = 4.3$ Hz, 2H), 7.62 (d, $J = 4.3$ Hz, 2H), 6.41 (d, $J = 2.1$ Hz, 2H), 6.29 (d, $J = 2.1$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 164.0, 147.1, 146.6, 146.1$,

136.0, 130.8, 127.3, 123.8, 121.8, 116.3, 112.1, 32.7, 14.8; MS (ESI): m/z $[M+H]^+ = 334.0$.

3,5-Dichloro-8-(4'-nitrophenyl)-4,4-difluoro-4-bora-3a,4a-diaza-s-indacence (3). To a solution of **2** (1.0 g, 2.97 mmol) in anhydrous CH_2Cl_2 (70 mL) was added *N,N*-diisopropylethylamine (3.1 mL, 17.8 mmol) stirred at 0 °C for 10 min. Boron trifluoride diethyl etherate (2.2 mL, 17.8 mmol) was added dropwise and the resulting mixture was stirred at rt for 2 h. Upon completion, solvents were removed *in vacuo* and the residue purified by flash column chromatography on silica gel (hexane:EtOAc:MeOH, 10:1:0.1) to afford **3** as a deep reddish-purple solid (0.81 g, 2.14 mmol, 72% yield). 1H NMR (300 MHz, $CDCl_3$): $\delta = 8.39$ (d, $J = 4.4$ Hz, 2H), 7.69 (d, $J = 4.4$ Hz, 2H), 6.75 (d, $J = 2.2$ Hz, 2H), 6.48 (d, $J = 2.2$ Hz, 2H); ^{13}C NMR (125 MHz, $CDCl_3$): $\delta = 162.4$, 148.4, 147.1, 132.0, 125.3, 126.8, 124.5, 123.8, 127.3, 120.8, 114.9, 111.3; ^{19}F NMR (282 MHz, $CDCl_3$): $\delta = -72.12$ (q, $J = 30$ Hz); MS (ESI): m/z $[M+H]^+ = 382.9$.

3,5-Dichloro-8-(4'-aminophenyl)-4,4-difluoro-4-bora-3a,4a-diaza-s-indacence (4). A suspension of iron powder (1.46 g, 26.2 mmol) was activated in 1M HCl for 1 min, rinsed with absolute EtOH and used as such. A solution of **3** (500 mg, 1.3 mmol) in EtOH (80 mL) and acetic acid (8 mL) was added the activated iron and refluxed. The reaction mixture was monitored by TLC. Upon completion, iron was removed and the solvent was evaporated *in vacuo*. The residue was diluted with water and extracted with CH_2Cl_2 (3 $\times$ 70 mL). The combined organic extracts were washed with saturated Na_2CO_3 , saturated brine, dried over anhydrous Na_2SO_4 and the solvents removed *in vacuo*. The residue was purified by flash column chromatography on silica gel (hexane:EtOAc:MeOH: NH_3 : 6:3:1:0.05) to afford **4** as a dark red solid (197 mg, 0.56 mmol, 98% yield). 1H NMR (300 MHz, $CDCl_3$): $\delta = 7.33$ (dt, $J = 8.5$, 2.6 Hz, 2H), 6.92 (d, $J = 3.8$ Hz, 2H), 6.76 (dt, $J = 8.5$, 2.6 Hz, 2H), 6.42 (d, $J = 3.8$ Hz, 2H), 4.11 (br. s, 2H); ^{13}C NMR (125 MHz, $CDCl_3$): $\delta = 162.4$, 147.6, 132.0, 128.7, 125.2, 26.9, 124.5, 120.8, 114.9, 111.3; ^{19}F NMR (282 MHz, $CDCl_3$): $\delta = -72.05$ (q, $J = 25$ Hz); HRMS ($C_{15}H_{11}BCl_2F_2N_3$): Calc. $[M+H]^+$: 352.0386, Found $[M+H]^+$: 352.0215.


10-(4-aminophenyl)-5,5-difluoro-7-(4-phenyl-1H-1,2,3-triazol-1-yl)-3-(piperidin-1-yl)-5H-dipyrrolo[1,2-*c*:2',1'-*f*][1,3,2]diazaborinin-4-ium-5-uide (BDC-9): Orange solid (17 mg, 0.032 mmol, 72% yield); 1H NMR (500 MHz, $CDCl_3$): $\delta = 8.56$ (s, 1H), 7.94 (d, J







= 6.9 Hz, 2H), 7.45 (t, $J = 7.6$ Hz, 2H), 7.35 (t, $J = 7.6$ Hz, 1H), 7.27 (d, 8.2 Hz, 2H),
 6.94 (d, $J = 5.7$ Hz, 1H), 6.80 (d, $J = 8.2$ Hz, 2H), 6.62 (d, $J = 3.8$ Hz, 1H), 6.42 (d, $J =$
 3.8 Hz, 1H), 6.32 (d, $J = 5.1$ Hz, 1H), 5.30 (s, 1H), 3.78 – 3.88 (m, 4H), 1.64 – 1.80 (m,
 6H), 1.26 (*br. s*, 2H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 162.2, 146.7, 136.0, 135.7,$
 5 134.9, 131.8, 131.3, 131.0, 130.8, 129.6, 128.7, 127.9, 126.0, 125.0, 122.4, 122.3, 116.9,
 115.4, 115.0, 114.9, 109.7, 53.4, 52.0, 29.7, 26.3, 24.0; ^{19}F NMR (282 MHz, CDCl_3): δ
 = -55.82 (q, $J = 34$ Hz); HRMS ($\text{C}_{28}\text{H}_{27}\text{BF}_2\text{N}_7$): Calc. $[\text{M}+\text{H}]^+$: 510.2384, Found
 $[\text{M}+\text{H}]^+$: 510.2399.







7-(benzylamino)-5,5-difluoro-10-(4-(2-hydroxyacetamido)phenyl)-3-(4-propyl-1H-
 10 1,2,3-triazol-1-yl)-5H-dipyrrolo[1,2-*c*:2',1'-*f*][1,3,2]diazaborinin-4-ium-5-uide
 (MKHA374-48): Orange solid (15 mg, 0.027 mmol, 61% yield); ^1H NMR (500 MHz,
 CDCl_3): $\delta = 8.91$ (s, 1H), 8.15 (s, 1H), 7.71 (d, $J = 8.2$ Hz, 2H), 7.33 – 7.39 (m, 5H),
 7.27 – 7.30 (m, 3H), 6.95 (d, $J = 5.0$ Hz, 1H), 6.74 (*br. s*, 1H), 6.38 (s, 2H), 6.20 (d, $J =$
 4.4 Hz, 1H), 4.60 (d, $J = 6.3$ Hz, 2H), 4.30 (s, 2H), 2.80 (t, $J = 7.6$ Hz, 2H), 1.80 (qt, J
 15 = 7.6 Hz, 2H), 1.03 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 170.8, 162.5,$
 139.0, 136.9, 136.1, 133.9, 132.4, 132.0, 131.8, 131.0, 129.2, 128.9, 128.4, 127.6, 126.8,
 119.6, 119.0, 112.5, 109.5, 62.6, 48.4, 28.7, 22.4, 13.7; ^{19}F NMR (282 MHz, CDCl_3): δ
 = -68.29 (q, $J = 33$ Hz); HRMS ($\text{C}_{29}\text{H}_{28}\text{BF}_2\text{N}_7\text{O}_2$): Calc. $[\text{M}+\text{H}]^+$: 556.2444, Found
 $[\text{M}+\text{H}]^+$: 556.2461.







20







Table 2. Chemical structures and characterization data for the BDC compound library.







Code	Structure	purity (254 nm)	m/z (calc.)	m/z (exper.)	λ_{max} Absorp. (nm)	λ_{max} Emission (nm)	ϕ (%)
BDC-1		95%	489.3	490.0	475	593	0.18







BDC-2		95%	490.3	491.0	469	587	0.13
BDC-3		98%	503.3	504.3	475	567	0.37
BDC-4		95%	473.2	474.2	475	590	0.16
BDC-5		99%	501.3	502.2	476	582	0.16
BDC-6		86%	515.4	516.2	473	582	0.24
BDC-7		99%	515.3	516.2	476	573	0.23

BDC-8		88%	529.3	503.2	473	585	0.24
BDC-9		97%	509.2	510.2	472	581	0.22
BDC-10		92%	523.3	524.2	470	564	0.28
BDC-11		97%	565.3	566.3	471	552	0.74
BDC-12		90%	565.3	566.3	473	594	0.09
BDC-13		97%	552.3	553.2	475	616	0.03

BDC-14		99%	569.3	570.2	473	578	0.18
BDC-15		84%	593.2	594.0	469	549	0.19
BDC-16		95%	545.2	546.1	471	585	0.18
BDC-17		99%	539.2	540.2	474	591	0.11
BDC-18		87%	566.3	567.3	471	580	0.18
BDC-19		98%	537.3	538.2	476	594	0.08

BDC-22		99%	589.3	590.2	472	579	0.28
BDC-23		99%	585.5	586.3	472	570	0.20
BDC-26		91%	545.2	546.2	473	585	0.12
BDC-27		58%	539.2	540.2	472	565	0.17
BDC-29		93%	579.3	580.3	471	586	0.23
BDC-30		92%	645.2	646.1	466	547	0.57

BDC-31		96%	527.2	528.2	470	582	0.11
BDC-36		98%	503.3	504.1	476	590	0.11
BDC-37		96%	513.3	514.2	474	579	0.12
BDC-42		92%	489.3	490.2	473	584	0.19
BDC-43		95%	489.3	490.2	476	589	0.10
BDC-44		94%	545.3	546.1	475	583	0.13

BDC-45		84%	523.3	524.2	469	556	0.42
BDC-46		98%	537.3	538.2	473	585	0.10
BDC-47		90%	517.3	518.2	473	574	0.16
BDC-48		96%	475.3	476.2	476	582	0.10
BDC-49		92%	573.4	574.2	475	589	0.12
BDC-50		93%	531.3	532.2	475	577	0.13




















BDC-67		99%	517.3	518.1	478	595	0.09
BDC-69		92%	533.3	534.2	476	586	0.13
BDC-70		99%	463.3	464.2	474	586	0.13






Table 3. Chemical structures and characterization data for the BDCAC compound library.






Code	Structure	Purity (254 nm)	m/z (calc.)	m/z (exper.)	λ_{max} Absorp. (nm)	λ_{max} Emission (nm)	ϕ (%)
BDCAC-1		95%	531.4	532.3	469	580	1.5






BDCAC-2		98%	532.4	533.3	466	591	0.8
BDCAC-3		97%	545.4	546.3	467	585	1.5
BDCAC-4		97%	515.4	516.2	467	578	1.5
BDCAC-5		99%	543.4	544.3	469	588	1.3
BDCAC-6		93%	557.5	558.1	467	560	2.4






BDCAC-7		98%	557.5	558.3	467	585	1.3
BDCAC-8		98%	571.5	572.3	468	585	0.9
BDCAC-9		97%	551.4	552.1	465	579	1.1
BDCAC-10		91%	565.4	566.2	464	556	2.4
BDCAC-11		96%	607.5	608.3	465	582	1.4

BDCAC-12		89%	607.5	608.3	464	558	1.6
BDCAC-13		98%	594.5	595.2	467	619	0.1
BDCAC-14		98%	611.5	612.3	464	588	1.0
BDCAC-15		84%	635.4	636.2	463	537	2.7
BDCAC-16		93%	587.4	588.2	462	586	0.7

BDCAC-17		99%	581.4	582.2	465	584	0.8
BDCAC-18		88%	608.5	609.3	465	588	0.8
BDCAC-19		98%	579.5	580.3	467	580	0.9
BDCAC-22		98%	631.5	632.2	465	585	1.2
BDCAC-23		99%	627.4	628.3	465	574	1.3

BDCAC-26		91%	587.4	588.2	465	567	1.3
BDCAC-27		89%	581.4	582.2	464	555	2.1
BDCAC-29		95%	621.5	622.3	465	561	1.6
BDCAC-30		93%	687.4	688.2	459	549	3.5
BDCAC-31		97%	569.4	570.1	463	569	0.9

BDCAC-36		99%	545.4	546.2	467	585	0.8
BDCAC-37		95%	555.4	556.3	466	565	1.9
BDCAC-42		98%	531.4	532.2	467	577	1.3
BDCAC-43		95%	531.4	532.2	467	581	0.8
BDCAC-44		95%	587.5	588.4	468	581	0.8

BDCAC-45		87%	565.4	566.2	463	551	3.2
BDCAC-46		99%	579.5	580.3	465	578	1.4
BDCAC-47		81%	559.5	560.3	467	562	1.4
BDCAC-48		95%	517.4	518.1	467	576	1.6
BDCAC-49		96%	615.6	616.4	467	575	1.3















BDCAC-50		94%	573.5	574.3	467	567	1.4
BDCAC-67		97%	559.4	560.3	469	592	0.8
BDCAC-69		92%	575.5	576.3	468	587	0.8
BDCAC-70		99%	505.3	506.0	467	583	0.7






Table 4. Chemical structures and characterization data for the BDCCA compound library.






5






Code	Structure	Purity (254 nm)	m/z (calc.)	m/z (exper.)	λ_{max} Absorp. (nm)	λ_{max} Emission (nm)	ϕ (%)
------	-----------	-----------------------	----------------	-----------------	---	--	------------






BDCCA-1		93%	565.9	566.2	468	581	0.7
BDCCA-2		52%	566.8	567.1	461	586	0.4
BDCCA-3		97%	579.9	580.2	467	587	0.9
BDCCA-4		92%	549.8	550.1	467	577	1.1
BDCCA-5		98%	577.9	578.3	468	588	0.9






BDCCA-6		80%	591.9	592.3	467	555	2.3
BDCCA-7		99%	591.9	592.3	468	590	0.9
BDCCA-8		79%	605.9	606.3	468	589	0.6
BDCCA-9		97%	585.8	586.1	464	577	1.1
BDCCA-10		90%	599.9	600.2	463	558	2.9






BDCCA-11		90%	642.0	642.3	464	587	1.3
BDCCA-12		91%	642.0	642.3	464	552	1.6
BDCCA-13		98%	628.9	629.3	467	627	0.1
BDCCA-14		97%	645.9	646.2	463	589	0.8
BDCCA-15		82%	669.8	670.2	462	537	2.2

BDCCA-16		93%	621.8	622.1	462	581	0.7
BDCCA-17		98%	615.9	616.2	464	584	0.7
BDCCA-18		87%	642.9	643.3	465	587	0.7
BDCCA-19		96%	613.9	614.2	466	578	1.0
BDCCA-22		97%	665.9	666.3	464	586	1.1

BDCCA-23		96%	661.9	662.2	464	575	1.2
BDCCA-26		89%	621.8	622.2	465	568	1.3
BDCCA-27		81%	615.9	616.2	463	552	2.3
BDCCA-29		90%	656.0	656.3	464	548	1.7
BDCCA-30		87%	721.8	722.2	458	556	2.6





BDCCA-31		94%	603.8	604.2	462	568	1.0
BDCCA-36		99%	579.9	580.3	467	584	0.5
BDCCA-37		95%	589.9	590.2	465	565	1.7
BDCCA-42		89%	565.9	566.1	467	577	1.3
BDCCA-43		94%	565.9	566.2	466	583	0.8






BDCCA-44		95%	621.3	622.3	466	582	0.7
BDCCA-45		81%	599.9	600.2	463	555	2.7
BDCCA-46		99%	613.9	614.1	464	568	1.2
BDCCA-47		89%	593.9	594.3	466	560	1.8
BDCCA-48		95%	551.8	552.2	466	569	1.4







BDCCA-49		90%	649.3	650.3	466	575	1.2
BDCCA-50		87%	607.9	608.3	466	568	1.0
BDCCA-67		87%	593.2	594.2	468	590	0.7
BDCCA-69		89%	609.9	610.3	467	587	0.7
BDCCA-70		93%	539.8	540.0	465	584	0.6

5







Table 5. Chemical structures and characterization data for the MK compound library.







Code	Structure	Purity (254 nm)	m/z (calc.)	m/z (exper.)	λ_{max} Absorp. (nm)	λ_{max} Emission (nm)	ϕ (%)
MK20-3		89%	533.29	534.7	476	573	0.10
MK20-4		87%	503.24	504.6	476	564	0.50
MK20-5		86%	531.27	532.7	476	580	0.57
MK20-8		89%	559.30	560.7	476	563	0.32







MK20-18		98%	596.30	597.7	477	582	0.23
MK20-19		95%	567.27	568.7	477	578	0.34
MK20-43		99%	519.27	520.6	478	584	0.23
MK20-48		89%	505.26	506.6	476	580	0.25
MK20-69		99%	563.30	564.7	480	586	0.16







MK20-70		99%	493.22	494.6	479	584	0.18
MK66-3		99%	551.28	552.7	479	579	0.16
MK66-4		99%	521.23	522.6	479	587	0.12
MK66-5		99%	549.26	550.6	481	582	0.19
MK66-8		99%	577.29	578.7	480	590	0.12
MK66-18		99%	614.29	615.7	478	587	0.14







MK66-19		99%	585.26	586.7	480	585	0.13
MK66-43		99%	537.26	538.6	480	582	0.14
MK66-48		99%	523.25	524.6	480	581	0.12
MK66-69		99%	581.29	582.7	480	583	0.14
MK66-70		99%	511.21	512.6	479	596	0.14
MK101-3		97%	539.28	540.7	475	562	1.08







MK101-4		99%	509.23	510.6	474	566	0.70
MK101-5		97%	537.26	538.6	475	565	0.58
MK101-8		94%	565.29	566.7	475	564	0.64
MK101-18		92%	602.29	603.7	474	563	0.179
MK101-19		82%	573.26	574.7	472	560	2.03
MK101-43		90%	525.26	526.7	474	562	2.36







MK101-48		90%	511.25	512.6	473	562	2.92
MK101-69		96%	569.29	570.7	475	563	2.40
MK101-70		87%	499.21	500.6	474	565	1.92
MK103-3		99%	569.29	570.7	474	564	1.71
MK103-4		95%	539.24	540.6	473	563	1.68
MK103-5		99%	567.27	568.6	473	564	2.01







MK103-8		98%	595.30	596.7	473	563	1.64
MK103-18		95%	632.30	633.7	473	565	1.19
MK103-19		95%	603.27	604.7	472	568	1.96
MK103-43		97%	555.27	556.7	474	563	1.30
MK103-48		96%	541.26	542.7	473	563	1.91
MK103-69		93%	599.30	600.7	474	563	2.28







MK103-70		98%	529.22	530.6	472	562	1.93
MK181-3		98%	585.28	586.7	473	565	0.36
MK181-4		99%	555.24	556.6	474	566	0.28
MK181-5		99%	583.27	584.7	475	563	0.43
MK181-8		99%	611.30	612.8	474	565	0.33
MK181-18		99%	648.29	649.7	473	563	0.52

MK181-19		99%	619.27	620.7	474	564	0.85
MK181-43		99%	571.27	572.6	475	566	0.37
MK181-48		99%	557.25	558.7	473	563	0.50
MK181-69		99%	615.29	616.7	473	563	0.86
MK181-70		99%	545.22	546.6	472	568	0.88
MK195-3		88%	539.28	540.7	476	564	0.46

MK195-4		86%	509.23	510.6	476	566	0.34
MK195-5		95%	537.26	538.6	477	579	0.39
MK195-8		95%	565.29	566.7	476	579	0.36
MK195-18		83%	602.29	603.7	475	580	0.52
MK195-19		92%	573.26	574.7	477	582	0.27
MK195-43		87%	525.26	526.6	475	571	0.41






MK195-48		91%	511.25	512.6	476	584	0.32
MK195-69		96%	569.29	570.7	476	591	0.28
MK195-70		99%	499.21	500.6	475	592	0.27
MK215-3		98%	489.26	490.6	471	567	0.26
MK215-4		99%	459.22	460.6	470	576	0.29
MK215-5		98%	487.25	488.6	471	568	0.53






MK215-8		97%	515.28	516.7	470	574	0.56
MK215-18		99%	552.27	553.7	471	583	0.24
MK215-19		99%	523.25	524.6	471	578	0.22
MK215-43		99%	457.25	476.6	471	571	0.33
MK215-48		99%	461.23	462.6	470	575	0.29
MK215-69		99%	519.27	520.6	470	580	0.33






MK215-70		99%	449.19	450.5	471	595	0.22
MK412-3		98%	561.24	562.6	476	562	0.63
MK412-4		99%	531.20	532.6	475	562	0.67
MK412-5		99%	559.23	560.6	476	567	0.68
MK412-8		99%	587.26	588.7	476	563	0.56
MK412-18		99%	624.25	625.7	473	563	1.02






MK412-19		99%	595.23	596.6	475	564	0.92
MK412-43		99%	547.23	548.6	476	564	0.86
MK412-48		97%	533.21	534.6	474	563	1.55
MK412-69		99%	591.25	592.6	476	563	1.98
MK412-70		59%	521.18	522.5	470	562	1.89






Table 6. Chemical structures and characterization data for the MKAC compound library.






Code	Structure	Purity (254 nm)	m/z Calculated	m/z Experimental	λ_{max} Abs. (nm)	λ_{max} Em. (nm)	ϕ (%)
MKAC20-3		96%	575.30	576.7	466	583	2.40
MKAC20-4		91%	545.25	546.6	466	585	3.64
MKAC20-5		95%	573.28	574.7	467	580	3.47
MKAC20-8		88%	601.31	602.7	466	583	4.98
MKAC20-18		99%	638.31	639.8	467	583	2.13






MKAC20-19		93%	609.28	610.7	467	579	3.12
MKAC20-43		99%	561.28	562.7	467	586	1.55
MKAC20-48		93%	547.27	548.7	467	581	2.93
MKAC20-69		99%	605.31	606.8	469	590	2.23
MKAC20-70		99%	535.23	536.6	467	586	1.33






MKAC66-3		99%	593.29	594.7	469	583	2.40
MKAC66-4		99%	563.24	564.6	469	580	2.56
MKAC66-5		99%	591.27	592.7	470	583	1.96
MKAC66-8		99%	619.30	620.7	469	578	2.20
MKAC66-18		99%	656.30	657.8	468	585	1.56






MKAC66-19		99%	627.27	628.7	470	580	1.76
MKAC66-43		99%	579.27	580.7	469	581	1.92
MKAC66-48		99%	565.26	566.7	469	582	2.14
MKAC66-69		99%	623.30	624.7	469	579	1.88
MKAC66-70		99%	553.22	554.6	468	582	1.44

MKA101-3		96%	581.29	582.7	464	562	21.57
MKAC10 1-4		99%	551.24	552.6	465	563	23.84
MKAC10 1-5		99%	579.27	580.7	466	563	23.69
MKAC10 1-8		97%	607.30	608.7	465	563	21.14
MKAC10 1-18		93%	644.30	645.7	465	362	13.14






MKAC10 1-19		83%	615.27	616.7	464	560	23.26
MKAC10 1-43		99%	567.27	568.6	465	562	20.12
MKAC10 1-48		90%	553.26	554.7	465	562	17.25
MKAC10 1-69		99%	611.30	612.7	461	562	24.08
MKAC10 1-70		99%	541.22	542.6	465	561	18.11







MKAC10 3-3		99%	611.30	612.7	465	561	23.42
MKAC10 3-4		99%	581.25	582.7	464	565	24.86
MKAC10 3-5		99%	609.28	610.7	465	562	18.11
MKAC10 3-8		97%	637.31	638.8	465	562	25.32
MKAC10 3-18		98%	674.31	675.8	465	560	18.63






MKAC10 3-19		93%	645.28	646.7	464	562	29.05
MKAC10 3-43		99%	597.28	598.7	465	560	22.79
MKAC10 3-48		99%	583.27	584.7	466	562	20.07
MKAC10 3-69		99%	641.31	642.7	465	561	20.91
MKAC10 3-70		99%	571.23	572.6	464	558	15.35







MKAC18 1-3		97%	627.29	628.7	465	562	15.41
MKAC18 1-4		99%	597.25	598.7	464	562	15.43
MKAC18 1-5		99%	625.28	626.7	464	563	10.37
MKAC18 1-8		99%	653.31	654.8	465	564	13.98
MKAC18 1-18		99%	690.30	691.7	464	561	18.28






MKAC18 1-19		99%	661.28	662.7	464	561	14.0
MKAC18 1-43		99%	613.28	614.7	467	562	13.79
MKAC18 1-48		99%	599.26	600.7	465	561	11.03
MKAC18 1-69		99%	657.30	658.8	465	561	16.50
MKAC18 1-70		99%	587.23	588.6	465	559	15.37

MKAC19 5-3		78%	581.29	582.7	465	574	6.53
MKAC19 5-4		83%	551.24	552.6	466	582	5.45
MKAC19 5-5		88%	579.27	580.7	467	578	4.18
MKAC19 5-8		78%	607.30	608.7	466	577	3.65
MKAC19 5-18		92%	644.30	645.7	465	575	1.85

MKAC19 5-19		76%	615.27	616.7	467	577	3.78
MKAC19 5-43		82%	567.27	568.7	466	580	3.48
MKAC19 5-48		88%	553.26	554.7	467	575	2.72
MKAC19 5-69		96%	611.30	612.7	467	560	3.467
MKAC19 5-70		99%	541.22	542.6	464	579	1.67
MKAC21 5-3		99%	531.27	532.6	461	569	3.81

MKAC21 5-4		99%	501.23	502.6	462	576	2.35
MKAC21 5-5		99%	529.26	530.6	463	574	1.00
MKAC21 5-8		82%	557.29	558.7	462	568	1.17
MKAC21 5-18		99%	594.28	595.7	461	569	1.54
MKAC21 5-19		99%	565.26	566.7	462	567	3.41

MKAC21 5-43		99%	517.26	518.6	461	565	1.83
MKAC21 5-48		99%	503.24	504.6	461	566	2.70
MKAC21 5-69		99%	561.28	562.7	462	566	2.00
MKAC21 5-70		93%	491.21	492.6	461	574	1.11
MKAC41 2-3		99%	603.25	604.7	466	561	27.73
MKAC41 2-4		99%	573.21	574.6	466	562	26.84

MKAC41 2-5		99%	601.24	602.7	467	560	27.51
MKAC41 2-8		99%	629.27	630.7	467	562	16.81
MKAC41 2-18		99%	666.27	667.7	465	561	21.83
MKAC41 2-19		99%	637.24	638.7	467	562	24.16
MKAC41 2-43		99%	589.24	590.7	467	560	18.26




















MKAC41 2-48		95%	575.22	576.7	467	561	22.19
MKAC41 2-69		99%	633.26	634.7	468	563	17.68
MKAC41 2-70		59%	563.19	564.6	461	561	3.96

Table 7. Chemical structures and characterization data for the MKCA compound library.






Code	Structure	Purity (254 nm)	m/z (calc.)	m/z (exper.)	λ_{max} Absorp. (nm)	λ_{max} Emission (nm)	ϕ (%)
MKCA20- 3		94%	609.26	610.7	467	581	3.15






MKCA20-4		92%	579.21	580.6	466	581	6.11
MKCA20-5		93%	607.24	608.7	468	581	4.60
MKCA20-8		86%	635.27	636.7	466	573	6.71
MKCA20-18		99%	672.27	673.7	466	585	2.54
MKCA20-19		95%	643.24	644.7	467	583	5.32






MKCA20-43		99%	595.24	596.7	468	585	2.19
MKCA20-48		89%	581.23	582.7	466	569	4.88
MKCA20-69		99%	639.27	640.7	469	586	3.23
MKCA20-70		99%	569.19	570.6	469	587	2.64
MKCA66-3		99%	627.25	628.7	469	582	3.50






MKCA66-4		99%	597.2	598.6	469	587	3.33
MKCA66-5		99%	625.23	626.7	470	587	3.11
MKCA66-8		99%	653.26	654.7	469	582	3.05
MKCA66-18		87%	690.26	691.7	466	585	2.33
MKCA66-19		99%	661.23	662.7	469	586	3.22






MKCA66-43		99%	613.23	614.7	469	581	3.04
MKCA66-48		99%	599.22	600.6	469	584	3.18
MKCA66-69		99%	657.26	658.7	469	586	3.38
MKCA66-70		99%	587.18	588.6	468	581	2.61
MKCA10 1-3		94%	615.25	616.7	464	563	31.22






MKCA10 1-4		99%	585.2	586.6	464	565	34.56
MKCA10 1-5		99%	613.23	614.7	466	563	31.53
MKCA10 1-8		99%	641.26	642.7	464	562	30.95
MKCA10 1-18		62%	678.26	679.7	462	562	21.53
MKCA10 1-19		93%	649.23	650.7	463	562	33.37






MKCA10 1-43		99%	601.23	602.6	466	562	29.92
MKCA10 1-48		88%	587.22	588.6	465	562	28.94
MKCA10 1-69		88%	645.26	646.7	466	562	21.93
MKCA10 1-70		78%	575.18	576.6	465	560	21.76
MKCA10 3-3		99%	645.26	646.7	466	562	23.61






MKCA10 3-4		91%	615.21	616.6	464	564	36.22
MKCA10 3-5		99%	643.24	644.7	464	563	33.46
MKCA10 3-8		92%	671.27	672.7	464	563	37.77
MKCA10 3-18		79%	708.27	709.7	462	561	24.66
MKCA10 3-19		97%	679.24	680.7	464	563	36.82






MKCA10 3-43		99%	631.24	632.7	465	563	33.76
MKCA10 3-48		92%	617.23	618.7	465	562	38.23
MKCA10 3-69		86%	675.27	676.6	465	562	33.49
MKCA10 3-70		99%	605.19	606.6	463	563	20.22
MKCA18 1-3		95%	661.25	662.7	465	564	21.77 54






MKCA18 1-4		99%	631.21	632.6	464	566	19.35
MKCA18 1-5		99%	659.24	660.7	465	560	25.80
MKCA18 1-8		99%	687.27	688.7	465	562	20.56
MKCA18 1-18		68%	724.27	725.7	462	563	21.65
MKCA18 1-19		99%	695.24	696.7	464	562	21.21






MKCA18 1-43		99%	647.24	648.7	465	564	21.21
MKCA18 1-48		99%	633.22	634.7	465	563	20.00
MKCA18 1-69		99%	691.26	692.7	465	558	14.25
MKCA18 1-70		99%	621.19	622.6	464	562	19.42
MKCA19 5-3		88%	615.25	616.7	466	577	7.95

MKCA19 5-4		86%	585.2	586.6	466	575	7.26
MKCA19 5-5		91%	613.23	614.7	467	580	4.93
MKCA19 5-8		93%	641.26	642.7	465	581	6.17
MKCA19 5-18		82%	678.26	679.7	462	580	3.03
MKCA19 5-19		90%	649.23	650.6	467	586	6.77

MKCA19 5-43		88.6	601.23	602.6	465	575	4.97
MKCA19 5-48		99%	537.22	538.6	466	583	5.43
MKCA19 5-69		95%	645.26	646.7	466	582	4.20
MKCA19 5-70		99%	575.18	576.6	465	581	2.58
MKCA21 5-3		92%	565.23	566.7	463	569	3.99

MKCA21 5-4		99%	544.19	536.6	462	570	3.35
MKCA21 5-5		86%	563.22	564.6	463	574	1.94
MKCA21 5-8		99%	591.25	592.6	463	564	2.66
MKCA21 5-18		99%	628.24	629.7	461	577	2.62
MKCA21 5-19		99%	599.22	600.6	463	573	4.98






MKCA21 5-43		99%	551.22	552.6	461	570	4.04
MKCA21 5-48		96%	537.2	538.6	462	565	4.60
MKCA21 5-69		58%	595.24	596.7	462	569	3.42
MKCA21 5-70		99%	525.17	526.6	459	568	1.97
MKCA41 2-3		98%	637.21	638.7	467	563	41.81

MKCA41 2-4		99%	607.17	608.6	467	563	36.25
MKCA41 2-5		97%	635.2	636.6	468	563	41.21
MKCA41 2-8		99%	663.23	664.7	467	564	36.92
MKCA41 2-18		62%	700.23	701.7	463	560	26.25
MKCA41 2-19		99%	671.2	672.6	466	563	42.58



MKCA41 2-43		99%	623.2	624.6	468	563	37.83
MKCA41 2-48		95%	609.18	610.6	466	561	36.09
MKCA41 2-69		99%	667.22	668.7	465	562	30.05
MKCA41 2-70		58%	596.15	598.6	464	562	6.28

Table 8. Chemical structures and characterization data for the MKHA compounds.

Code	Structure	Purity (254 nm)	m/z (calc.)	m/z (exper.)	$\lambda_{\max}$ Absorp. (nm)	$\lambda_{\max}$ Emission (nm)	ϕ (%)
------	-----------	-----------------------	----------------	-----------------	-------------------------------------	--------------------------------------	------------

MKHA10 1-3		99%	597.47	598.2	468	560	0.4121
MKHA10 3-3		95%	627.49	628.2	470	556	0.2361
MKHA37 4-3		98%	583.44	584.2	470	557	0.4121
MKHA38 1-3		99%	613.47	614.2	470	556	0.4258
MKHA52 2-3		99%	639.55	640.4	470	559	0.4181

MKHA10 1-1		99%	583.44	584.4	469	556	0.3122
MKHA10 1-4		96%	567.40	568.2	469	558	0.3456
MKHA10 1-42		97%	583.44	584.2	469	560	0.3153
MKHA10 1-43		99%	583.44	584.2	468	558	0.0498
MKHA37 4-1		99%	569.42	570.2	470	558	0.399

MKHA37 4-4		96%	553.37	554.2	469	558	0.3682
MKHA37 4-48		97%	555.39	556.2	468	557	0.3684

Example 2. Analysis of Amino-Triazolyl BODIPY Compounds as Fluorescent Molecular Rotors.

- 5 The fluorescence spectra of compound (BDC-9) in different solvents of similar polarities but covering a range of viscosities were analyzed. As shown in FIG. 3, a strong correlation between fluorescence intensity and viscosity was observed. Increased solvent viscosity reduces bond rotation at positions 3 and 5 of the BODIPY core, which, without being bound to theory, minimizes non-radiative energy loss and leads to higher quantum yields (24). This result confirms the potential of amino-triazolyl BODIPYs as
- 10 fluorescent molecular rotors.

Example 3. Identification of a Selective HSA Fluorescent Probe

Materials and Methods

- 15 Mixtures of BDC-9 with HSA were prepared in phosphate buffer (pH 7.3, 1% DMSO) at room temperature and fluorescence measurements were taken after incubation for 2 h unless otherwise stated.

In vitro fluorescence screening

- 20 Amino-triazolyl-BODIPYs (10 μ M) were screened in 10 mM HEPES buffer, pH 7.4, containing 1% DMSO. Fluorescence intensities were measured using a SpectraMax M2 platereader in 384-well plates. Excitation was provided at each compound's

excitation range, and emission spectrum was obtained starting from at least 30 nm beyond the excitation wavelength. All the analytes were tested at four serial concentrations.

The fluorescent response of BDC, BDCAC and BDCCA was examined against 84 biologically relevant analytes that were categorized into nine different sets (*i.e.* pH standards, viscous solutions, genetic macromolecules, peptides, metal ions, redox molecules, nucleic acids, proteins and other metabolites). Amino-triazolyl-BODIPY compounds showed significant fluorescence increase upon incubation with certain specific proteins. As a representative example, the compound BDC-9 displayed a remarkable selectivity towards human serum albumin (HAS) when compared to other proteins and analytes (FIG. 4).

In addition to its high selectivity, BDC-9 showed a significant 220-fold increase in fluorescence upon binding to HSA (FIG. 5). The response of BDC-9 proved to be linear within a dynamic range between 0.37 and 31 $\mu\text{g/mL}$, and the limit of detection of HSA (S/N = 3) was determined as 0.3 $\mu\text{g/mL}$ (FIG. 6).

The selectivity of BDC-9 towards serum albumins from different species was investigated. Serum albumins represent a family of proteins with a high degree of similarity in their primary sequence across various species (~75% homology) (34,39,40,62). Yet, some albumin ligands have been found to show species dependent binding differences, and the development of species-selective probes may be useful for structural studies of albumin binding sites (63-67). The fluorescence response of BDC-9 was evaluated against serial concentrations of serum albumins from rat (RSA), porcine (PSA), rabbit (RbSA), sheep (SSA) and bovine (BSA). As shown in FIGs. 7a-b, BDC-9 displayed a marked selectivity towards HSA with marginal response on the other species (68,69).

Example 4. Analysis of the Binding of BDC-9 at HSA

The binding properties of BDC-9 were studied. HSA consists of at least nine binding sites (34-38), amongst which fatty acid (FA) sites 1, 3 and 4 (Sudlow Site II), 5, 6 and 7 (Sudlow Site I) are known to have affinity for drug compounds (31,39-44). A recent report has demonstrated the importance of the third major drug binding site on HSA, which corresponds to Fatty Acid 1 site (FA1) (70). To verify specific binding and

determine the binding site(s) of BDC-9 in HSA, competition assays using drugs binding to the respective sites (*e.g.* hēmin (FA1 site)(71,72), dansyl-*L*-norvaline (FA3/4 sites) (73), propofol (FA3/4 and FA5 sites) (35), ibuprofen (FA3/4 and FA6 sites) (74) and warfarin (FA7 site) (74) were performed (75).

5 As illustrated in FIG. 8, only the competition with hemin induced a significant decrease in the fluorescent response of BDC-9 while the competition with all other drugs did not affect the fluorescence of BDC-9. These observations clearly indicate that the environmental turn-on response of BDC-9 is due to its binding to the FA1 site (heme site) of HSA. There have been several reports of fluorescent dyes binding to FA3/4
10 (48,49,73), FA6 (51) and FA7 (54,55,76) sites. The present invention represents the first known experimentally proven fluorescent dye binding to the FA1 site (76), in which binding is not dependent on contact with bound lipid (72). BDC-9 is therefore a valuable probe for examining the heme region on HSA.

A Job plot analysis was performed to determine the stoichiometry of the
15 complex formed by BDC-9 and HSA, and confirm the results from the site-selectivity studies. The fluorescence response of BDC-9 peaked at a 1:1 proportion of BDC-9:HSA, which indicates that BDC-9 binds mainly at one site of the protein (FIG. 9) (77,78).

Determination of dissociation constant for BDC-9 with HSA.

20 HSA (10 μM) was titrated against serial concentrations of BDC-9 (0.47 to 60 μM) and the fluorescence intensities were measured at 575 nm ($\lambda_{exc} = 460$ nm). The fluorescence intensity of bound BDC-9 at each concentration was determined using the equation:

$$F_{bound} = \frac{F_{sat}(F - F_0)}{(F_{sat} - F_0)}$$

25 where F and F_0 are the fluorescence intensities of a given concentration of BDC-9 with and without HSA respectively. F_{sat} is the fluorescence intensity at the same concentration of BDC-9 when fully bound.

A one-site binding model was fitted to the titration of HSA (0.67 mg/mL) with serial concentrations of BDC-9, and the dissociation constant (K_D) of BDC-9 was
30 determined to be 12.7 ± 0.4 μM (FIG. 10).

Example 5. Application of BDC-9 to quantify HSA in urine

In order to examine the selectivity and sensitivity of BDC-9 in complex matrices, BDC-9 was utilized to quantify the amount of HSA in urine samples.

5 Microalbuminuria, which involves an albumin excretion rate of 15 to 40 $\mu\text{g/mL}$ (80, 81), is a well-established cardiovascular risk marker and an indication of liver and renal disease (32,33). The fluorescence response of BDC-9 was analyzed in urine that was spiked with different amounts of HSA, up to 1 mg/mL. An excellent linear correlation existed between the fluorescence response of BDC-9 and the amount of HSA in a
10 clinically-significant range (FIG. 11), which proves the potential of BDC-9 to quantify HSA levels in urine samples.

Example 6. Discovery of MKHA and NeuO Neural Cell Probes

In a preliminary cell-based screening of the 2nd generation amino-triazolyl-BODIPY compounds (MK, MKAC, MKCA), MKCA compounds showed some weak
15 response towards primary neurons. Subsequent conversion into the MKHA derivatives generally improved the fluorescence response towards primary neurons significantly (FIG. 12). Esterification to MKAA (and possibly other esters) improves permeability into intact live cells while maintaining staining specificity (FIG. 12). The acetylated
20 MKAA undergoes rapid hydrolysis by cellular esterases after crossing the live cell membrane generates the active MKHA compound responsible for the fluorescence response. FIGs. 13 and 14 show the structures of example MKHA compounds that have been synthesized and tested for primary neuron staining.

For neuron probe discovery, a primary brain cell screening platform was utilized,
25 which involved the use of primary neurons, astrocytes and microglia isolated by differential adhesion methods. These cells were prepared alongside one another in 384-well microplates and incubated in duplicate with 5,000 DOFL compounds at 500 nM concentrations for 1 hour at 4-5 days post-isolation (FIG. 15). Through an automatic intensity-based analysis and image-based evaluation, a primary fluorescent probe
30 specific for neurons, MKHA101-3, was identified. Preliminary structure activity relationship (SAR) studies were performed and an improved compound, MKHA374-48, was discovered which exhibited superior selectivity towards live neurons compared to

the original MKHA101-3 (FIG. 16). The compound MKHA374-48 is alternately referred to herein as NeuO (pronounced "neo") for Neuron Orange.

Example 7. NeuO is Specific for Live Neurons

Cell imaging with MKHA101-3

5 MKHA101-3 stains the cell bodies and dendrites specifically over other neural cells. Using the heterogeneous brain cell preparations from P1-P3 mice, cells that were compound positive were also found to be β -III-tubulin positive (FIG. 17). Other cells that tested positive for the astrocyte marker, GFAP and the oligodendrocyte marker O4 were found to be compound negative thus demonstrating the specificity of MKHA101-3
10 compound for neurons.

Cell imaging with NeuO

 NeuO stains the cell bodies and dendrites specifically over other neural cells. Using the heterogeneous brain cell preparations from P1-P3 mice, cells that were compound positive were also found to be β -III-tubulin (Tuji) positive (FIG. 18a). Other cells that
15 tested positive for the astrocyte marker, GFAP and the oligodendrocyte marker, O4 were found to be compound negative thus demonstrating the specificity of our compound for neurons. NeuO appears to stain all neurons regardless of subtype (FIG. 18b).

Flow cytometry analysis and FACS sorting

20 Flow cytometry analysis on mixed populations of cells prepared from the brains of P1-3 mouse pups also showed a clear population of cells (10-20%) segregating from the main population (FIG. 19). To further analyze this population of compound positive cells, the two populations (Bright and Dim) were sorted out cell re-culture and RNA extraction for gene analysis.

25 *Compound positive cells isolated from FACS show a neuronal morphology and are β -III-tubulin positive.*

 Compound bright and dim cells were sorted out and seeded for re-culture at a density of 50,000 cells/cm² in neurobasal media supplemented with B27 and FGF (10 ng/ μ L) on poly-D-lysine coated plates. After 5 days, cells with a neuronal morphology,
30 characterized by the extension of dendrites were observed in the compound bright reculture fraction (FIG. 20a). These cells were subsequently immunostained for the

neuronal marker, β -III-tubulin and found to be positive (FIG. 20b and c). Compound dim reculture fractions showed few if any cell growth reminiscent of neurons.

Compound positive cells show high expression of the neuronal marker, β -III tubulin.

The gene expression of the neuronal marker, β -III-tubulin, was analyzed from the RNA extracted from FACS sorted compound positive neuronal populations. Compound bright fractions consistently showed high β -III-tubulin expression (up to 10-fold higher) than compound dim fractions (FIG. 21). β -III-tubulin expression was also often up to 2-fold higher in compound bright fractions compared to unsorted fractions thus suggesting that the probe compound.

10 *Neurons remain viable after staining.*

For long term tracking and downstream functional studies, it is critical that the compound is not cytotoxic towards the cells and that cells remain viable after staining. A cell cytotoxicity assay (MTS, Promega) demonstrated that 24 hour incubation with NeuO did not affect cell viability significantly at working concentrations of 500nM or higher (FIG. 22).

NeuO can be used for long term imaging of in vitro neuronal development.

To test the potential of NeuO as a neuronal cell tracker, freshly harvested neurons from P1-3 mouse pups were stained and their dendrite formation was observed *in vitro* using time l imaging (FIG. 23). The survival of the cells and dye signal is critical in time lapse studies to analyze neuronal development and interaction with other neural cells.

Example 8. MKHA Compounds and other Neuron Imaging Applications

Based on SAR studies, additional compounds were designed and synthesized for various applications including covalent binding (FIG. 24), pull-down (FIGs. 24 and 25), PET imaging (FIG. 26) and near-infrared spectroscopy (FIG. 27). All compounds depicted in FIGs. 24-27 were found to stain live neurons.

Example 9. MKHA Compounds have the potential to label neurons specifically in the live mouse brain.

30 To access the potential of the dyes disclosed herein for live brain slice staining, fresh embryo brain slices were stained with the compounds and imaged under a fluorescence microscope. MKHA101-3 and its derivated shows a specific cellular

labeling pattern, with the dyes highlighting cells with long dendritic processes and cell bodies clustering in a manner that is consistent with a neuronal pattern (FIG. 28). This strongly suggests that the dyes can be further applied for the imaging of neurons in brain slice preparations.

5

References

1. O. Buyukcakil, *et al.*, *Org. Lett.* **11**, (2009), 4644-4647.
2. C. Yu *et al.*, *Chem. - Eur. J.* **18**, (2012), 6437-6442.
- 10 3. A. Martin, *et al.*, *Chem. Commun.* **48**, (2012), 5617-5619.
4. K. Umezawa, *et al.*, *J. Am. Chem. Soc.* **130**, (2008), 1550-1551.
5. J. Bañuelos, *et al.*, *Chem. - Eur. J.* **2011**, *17*, 7261-7270.
6. A. Loudet, K. Burgess, *Chem. Rev.* **2007**, *107*, 4891-4932.
7. G. Ulrich, R. Ziessel, A. Harriman, *Angew. Chem., Int. Ed.* **2008**, *47*, 1184-1201.
- 15 8. C. Bernhard, *et al.*, *Chem. Commun.* **2010**, *46*, 8267-8269.
9. J. A. Hendricks, *et al.*, *Angew. Chem., Int. Ed.* **2012**, *51*, 4603-4606.
10. J.-S. Lee, *et al.*, *J. Am. Chem. Soc.* **2009**, *131*, 10077-10082.
11. L. D. Lavis, R. T. Raines, *ACS Chem. Biol.* **2008**, *3*, 142-155.
12. M. Vendrell, *et al.*, *Chem. Commun.* **2011**, *47*, 8424.
- 20 13. M. Vendrell, D. Zhai, J. C. Er, Y.-T. Chang, *Chem. Rev.* **2012**, *112*, 4391-4420.
14. M. Meldal, C. W. Tornøe, *Chem. Rev.* **2008**, *108*, 2952-3015.
15. K. Sivakumar, *et al.*, *Org. Lett.* **2004**, *6*, 4603-4606.
16. D. K. Scafton, *et al.*, *J. Org. Chem.* **2008**, *73*, 2871-2874.
17. J. Han, *et al.*, *Org. Biomol. Chem.* **2009**, *7*, 34-36.
- 25 18. X. Qian, *et al.*, *Chem. Commun.* **2010**, *46*, 6418-6436.
19. W. Qin, *et al.*, *J. Phys. Chem. A* **2007**, *111*, 8588-8597.
20. B. Verbelen, *et al.*, *Chem. Commun.* **2012**, *48*, 9129-9131.
21. T. Rohand, *et al.*, *Chem. Commun.* **2006**, 266-268.
22. T. Rohand, *et al.*, *Photochem. Photobiol. Sci.* **2007**, *6*, 1061-1066.
- 30 23. V. Leen, *et al.*, *Chem. Commun.* **2010**, *46*, 4908-4910.
24. W. Qin, *et al.*, *J. Phys. Chem. C* **2009**, *113*, 11731-11740.
25. B. Temelli, C. Unaleroglu, *Tetrahedron* **2006**, *62*, 10130-10135.
26. L. Li, B. Nguyen, K. Burgess, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3112-3116.

27. L. Li, J. Han, B. Nguyen, K. Burgess, *J. Org. Chem.* **2008**, 73, 1963-1970.
28. O. A. Bozdemir, *et al.*, *J. Am. Chem. Soc.* **2010**, 132, 8029-8036.
29. A. Coskun, E. Deniz, E. U. Akkaya, *Org. Lett.* **2005**, 7, 5187-5189.
30. W. Qin, *et al.*, *J. Phys. Chem. A* **2008**, 113, 439-447.
- 5 31. G. Fanali, *et al.*, *Mol. Aspects Med.* **2012**, 33, 209-290.
32. D. J. F. Rowe, A. Dawnay, G. F. Watts, *Ann. Clin. Biochem.* **1990**, 27, 297-312.
33. C. E. Mogensen, O. Schmitz, *Med. Clin. North Am.* **1988**, 72, 1465-1492.
34. S. Curry, *et al.*, *Nat. Struct. Mol. Biol.* **1998**, 5, 827-835.
35. A. A. Bhattacharya, T. Grüne, S. Curry, *J. Mol. Biol.* **2000**, 303, 721-732.
- 10 36. I. Petitpas, *et al.*, *J. Mol. Biol.* **2001**, 314, 955-960.
37. I. Petitpas, *et al.*, *Proc. Natl. Acad. Sci.* **2003**, 100, 6440-6445.
38. S. Sugio, *et al.*, *Protein Eng.* **1999**, 12, 439-446.
39. S. Curry, *et al.*, *Biochim. Biophys. Acta, Mol. Cell Biol. L.* **1999**, 1441, 131-140.
40. S. Curry, *Drug Metab. Pharmacokinet.* **2009**, 24, 342-357.
- 15 41. L. Zhu, *et al.*, *J. Struct. Biol.* **2008**, 162, 40-49.
42. J. R. Simard, *et al.*, *Proc. Natl. Acad. Sci.* **2005**, 102, 17958-17963.
43. G. Sudlow, D. J. Birkett, D. N. Wade, *Mol. Pharmacol.* **1976**, 12, 1052-1061.
44. G. Sudlow, D. J. Birkett, D. N. Wade, *Mol. Pharmacol.* **1975**, 11, 824-832.
45. F. Moreno, *et al.*, *Photochem. Photobiol.* **1999**, 70, 695-700.
- 20 46. K. Takehara, *et al.*, *Anal. Sci.* **2009**, 25, 115-120.
47. X.-t. Chen, Y. Xiang, A.-j. Tong, *Talanta* **2010**, 80, 1952-1958.
48. F. Ding, W. Liu, J.-X. Diao, Y. Sun, *J. Hazard. Mater.* **2011**, 186, 352-359.
49. K. K. Park, J. W. Park, A. D. Hamilton, *Org. Biomol. Chem.* **2009**, 7, 4225-4232.
- 25 50. M. Banerjee, *et al.*, *J. Photochem. Photobiol. B* **2012**, 108, 23-33.
51. Y. Wang, *et al.*, *Protein Sci.* **2011**, 20, 2095-2101.
52. D. C. Wilton, *Biochem. J.* **1990**, 270, 163-166.
53. B. Sengupta, P. K. Sengupta, *Biopolymers* **2003**, 72, 427-434.
54. F. Moreno, *et al.*, *Photochem. Photobiol.* **1999**, 69, 8-15.
- 30 55. Y. Sun, *et al.*, *J. Lumin.* **2012**, 132, 879-886.
56. J. Rohacova, *et al.*, *J. Phys. Chem. B* **2011**, 115, 10518-10524.
57. E. Alarcon, *et al.*, *Photochem. Photobiol. Sci* **2010**, 9, 93-102.

58. Z.-d. Qi, *et al.*, *J. Pharm. Biomed. Anal.* **2008**, 46, 699-706.
59. S. Deepa, A. K. Mishra, *J. Pharm. Biomed. Anal.* **2005**, 38, 556-563.
60. F.-L. Cui, J.-L. Wang, Y.-R. Cui, J.-P. Li, *Anal. Chim. Acta* **2006**, 571, 175-183.
61. A.-I. Tsai, *et al.*, *Biochim. Biophys. Acta, Gen. Subj.* **1989**, 993, 74-82.
- 5 62. S. Curry, *Vol. 33*, **2004**, pp. 29-46.
63. M. Pistolozzi, C. Bertucci, *Chirality* **2008**, 20, 552-558.
64. N. E. Basken, *et al.*, *Nucl. Med. Biol.* **2008**, 35, 281-286.
65. C. J. Mathias, S. R. Bergmann, M. A. Green, *J. Nucl. Med.* **1995**, 36, 1451-1455.
66. J. J. Lima, *Drug Metab. Dispos.* **1988**, 16, 563-567.
- 10 67. N. E. Basken, C. J. Mathias, M. A. Green, *J. Pharm. Sci.* **2009**, 98, 2170-2179.
68. A. Baldridge, *et al.*, *ACS Comb. Sci.* **2011**, 13, 214-217.
69. Y.-H. Ahn, J.-S. Lee, Y.-T. Chang, *J. Comb. Chem.* **2008**, 10, 376-380.
70. F. Zsila, *Mol. Pharmaceutics* **2013**, 10, 1668-1682.
71. P. Zunszain, *et al.*, *BMC Struct. Biol.* **2003**, 3, 6.
- 15 72. M. Wardell, *et al.*, *Biochem. Biophys. Res. Commun.* **2002**, 291, 813-819.
73. A. J. Ryan, *et al.*, *J. Struct. Biol.* **2011**, 174, 84-91.
74. J. Ghuman, *et al.*, *J. Mol. Biol.* **2005**, 353, 38-52.
75. G. Zhang, N. Zhao, L. Wang, *J. Lumin.* **2011**, 131, 2716-2724.
76. K. Park, J. Park, A. Hamilton, *J. Fluoresc.* **2007**, 17, 361-369.
- 20 77. R. Subramanyam, *et al.*, *J. Photochem. Photobiol. B* **2009**, 95, 81-88.
78. C. Y. Huang, *Meth. Enzymol.* **1982**, 87, 509-525.
79. P. Job, *Ann. Chim. Anal.* **1928**, 9, 113-203.
80. M. A. Kessler, *et al.*, *Anal. Biochem.* **1997**, 248, 180-182.
81. M. A. Kessler, *et al.*, *Clin. Chem.* **1997**, 43, 996-1002.
- 25 82. J. DeFeliipe, *Science* **2010**, 330, 1198-1201.
83. C. Köbbert, *et al.*, *Prog. Neurobiol.* **2000**, 62, 327-351.
84. M. G. Honig, R. I. Hume, *Trends Neurosci.* **1989**, 12, 333-341.
85. S. M. Appleyard, *Endocrinology* **2009**, 150, 5199-5201.
86. K. Duff, F. Suleman, *Brief. Funct. Genomic Proteomic* **2004**, 3, 47-59.
- 30 87. H. Okano, *et al.*, *Parkinsonism Relat. D.* **2002**, 9, 23-28.
88. G. J. Brewer, *J. Neurosci. Meth.* **1997**, 71, 143-155.
89. S. Tolu, *et al.*, *FASEB J.* **2010**, 24, 723-730.


~~The teachings of all patents, published applications and references cited herein~~
are incorporated by reference in their entirety.

- 5 While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

CLAIMS

What is claimed is:

1. A compound having the structure of Formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ is H or CO(C₁-C₆)alkyl, wherein CO(C₁-C₆)alkyl is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or -NH₂;

R² and R³ are each, independently, H, (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₁₀)heteroaryl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl or (C₂-C₁₀)alkenyl;


wherein (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₁₀)heteroaryl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl and (C₂-C₁₀)alkenyl are optionally substituted at any position with 1-5 substituents selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, NH₂, -NH(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ haloalkyl), -NH(CO)(C₁-C₆ alkoxy), -NH(CO)(C₁-C₆ haloalkoxy), -NH(CO)(C₂-C₆ alkenyl), -Si(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SH, -B(OH)₂, -OTosyl, -CO(C₁-C₆ alkoxyl), -COH, -COOH, -CO(C₁-C₆ alkyl) or halogen;

or R² and R³ are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or (C₁-C₆)alkyl; and

R⁴ is (C₁-C₁₀)alkyl, (C₃-C₈)cycloalkyl, (C₆-C₁₀)aryl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, or (C₃-C₁₀)heteroaryl, further wherein R⁴ is optionally substituted at any position with 1-5 substituents selected from (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₃-C₈)cycloalkyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, (C₆-C₁₀)aryl, amino, -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₂-C₆ alkenyl), -NH(CO)(C₂-C₆ alkynyl), -NH(CO)(C₁-C₆ haloalkyl), halo, OCF₃, CF₃, hydroxyl, or a halogen radioisotope.


2. The compound of claim 1, wherein R^1 is H, COCH_3 , COCH_2Cl , COCH_2OH , COCH_2NH_2 , or $\text{COCH}_2\text{O}(\text{CO})\text{CH}_3$.

3. The compound of claim 2, having the structure of Formula (II):




or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2, having the structure of Formula (III):




or a pharmaceutically acceptable salt thereof.

5. The compound of claim 2, having the structure of Formula (IV)



or a pharmaceutically acceptable salt thereof.


6. The compound of claim 2, having the structure of Formula (V):



or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein the compound is conjugated to a chemical reactive moiety selected from biotin, diazirine, acryloyl, haloacetyl, diaaziridine, N-hydroxysuccinimide ester, imidoester, pentafluorophenyl ester, hydroxymethyl phosphine, maleimide, pyridyldisulfide, thiosulfonate, vinylsulfone, hydrazide, alkoxyamine, aryl azide, benzophenone, isocyanate, alkyne or ketone.

8. A method for a solid phase synthesis of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ is H or CO(C₁-C₆)alkyl, wherein CO(C₁-C₆)alkyl is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or -NH₂;

R² and R³ are each, independently, H, (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₁₀)heteroaryl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl or (C₂-C₁₀)alkenyl;


wherein (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₁₀)heteroaryl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl and (C₂-C₁₀)alkenyl are optionally substituted at any position with 1-5 substituents selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, NH₂, -NH(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ haloalkyl), -NH(CO)(C₁-C₆ alkoxy), -NH(CO)(C₁-C₆ haloalkoxy), -NH(CO)(C₂-C₆ alkenyl), -Si(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SH, -B(OH)₂, -OTosyl, -CO(C₁-C₆ alkoxy), -COH, -COOH, -CO(C₁-C₆ alkyl) or halogen;

or R² and R³ are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or (C₁-C₆)alkyl; and


R⁴ is (C₁-C₁₀)alkyl, (C₃-C₈)cycloalkyl, (C₆-C₁₀)aryl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, or (C₃-C₁₀)heteroaryl, further wherein R⁴ is optionally substituted at any position with 1-5 substituents selected from (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₃-C₈)cycloalkyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, (C₆-C₁₀)aryl, amino, -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₂-C₆ alkenyl), -NH(CO)(C₂-C₆ alkynyl), -NH(CO)(C₁-C₆ haloalkyl), halo, OCF₃, CF₃, hydroxyl, or a halogen radioisotope;

the method comprising:


(a) reacting a compound of Formula (VI):




with an azide under conditions sufficient to form a bis(azido)BODIPY compound of formula (VII):



(b) reacting the compound of Formula (VII) with an amine of the formula $\text{R}^2\text{R}^3\text{NH}$ under conditions sufficient to form a compound of Formula (VIII):



(c) reacting the compound of Formula (VIII) with an alkyne of the formula $\text{R}^4-\text{C}\equiv\text{CH}$ in the presence of a copper (I) catalyst under conditions sufficient to form a compound of Formula (IX):




(d) removing the solid support resin from the compound of Formula (IX) to form an unbound BODIPY compound where R^1 in Formula (I) is H; and

(e) optionally reacting the unbound BODIPY compound of step d) with an acid chloride of the formula $R^1\text{COCl}$ to form a compound of Formula (I) where R^1 is $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted with 1-3 substituents selected from halogen, O-acetyl, or N-acetyl.

9. The method of claim 8, wherein when step (e) is performed, the method comprises an additional step of treating the reaction mixture with a base under conditions sufficient to saponify an ester or amide linkage, wherein R^1 is $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted with 1-3 hydroxyl or $-\text{NH}_2$ substituents.

10. A method for a solution phase synthesis of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 is H or $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$, wherein $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or $-\text{NH}_2$;

R^2 and R^3 are each, independently, H, $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_0\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$ or $(\text{C}_2\text{-C}_{10})\text{alkenyl}$;


wherein (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl(C₀-C₆)alkyl, (C₃-C₁₀)heteroaryl, (C₃-C₈)cycloalkyl, (C₂-C₁₀)alkynyl and (C₂-C₁₀)alkenyl are optionally substituted at any position with 1-5 substituents selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, NH₂, -NH(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₁-C₆ haloalkyl), -NH(CO)(C₁-C₆ alkoxy), -NH(CO)(C₁-C₆ haloalkoxy), -NH(CO)(C₂-C₆ alkenyl), -Si(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SH, -B(OH)₂, -OTosyl, -CO(C₁-C₆ alkoxy), -COH, -COOH, -CO(C₁-C₆ alkyl) or halogen;

or R² and R³ are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or (C₁-C₆)alkyl; and


R⁴ is (C₁-C₁₀)alkyl, (C₃-C₈)cycloalkyl, (C₆-C₁₀)aryl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, or (C₃-C₁₀)heteroaryl, further wherein R⁴ is optionally substituted at any position with 1-5 substituents selected from (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₃-C₈)cycloalkyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, (C₆-C₁₀)aryl, amino, -NH(CO)(C₁-C₆ alkyl), -NH(CO)(C₂-C₆ alkenyl), -NH(CO)(C₂-C₆ alkynyl), -NH(CO)(C₁-C₆ haloalkyl), halo, OCF₃, CF₃, hydroxyl, or a halogen radioisotope;

the method comprising:


(a) reacting a compound of Formula (X):




with an azide under conditions sufficient to form a bis(azido)BODIPY compound of formula (XI):



(b) reacting the compound of Formula (XI) with an amine of the formula R²R³NH under conditions sufficient to form a compound of Formula (XII):



(c) reacting the compound of Formula (XII) with an alkyne of the formula $R^4-C\equiv CH$ in the presence of a copper (I) catalyst under conditions sufficient to form a compound of Formula (XIII):




(d) reducing the NO_2 group in the compound of Formula (XIII) to form a BODIPY compound where R_1 in Formula (I) is H; and

(e) optionally reacting the BODIPY compound of step d) with an acid chloride of the formula R^1COCl to form a compound of Formula (I) where R^1 is $CO(C_1-C_6)alkyl$ optionally substituted with 1-3 substituents selected from halogen, O-acetyl, or N-acetyl.

11. The method of claim 10, wherein when step (e) is performed, the method comprises an additional step of treating the reaction mixture with a base under conditions sufficient to saponify an ester or amide linkage, wherein R_1 is $CO(C_1-C_6)alkyl$ optionally substituted with 1-3 hydroxyl or $-NH_2$ substituents.

12. A method for detecting human serum albumin (HSA) in a sample of a biological fluid, comprising:

a) contacting a sample of biological fluid thought to contain HSA with the compound of claim 1 represented by Formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 is H or $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$, wherein $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or -NH_2 ;

R^2 and R^3 are each, independently, H, $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_0\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$ or $(\text{C}_2\text{-C}_{10})\text{alkenyl}$;

wherein $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_0\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$ and $(\text{C}_2\text{-C}_{10})\text{alkenyl}$ are optionally substituted at any position with 1-5 substituents selected from $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, NH_2 , $\text{-NH}(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkoxy})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkoxy})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkenyl})$, $\text{-Si}(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-SO}_2(\text{C}_1\text{-C}_6\text{ alkyl})$, -SH , $\text{-B}(\text{OH})_2$, -OTosyl , $\text{-CO}(\text{C}_1\text{-C}_6\text{ alkoxy})$, -COH , -COOH , $\text{-CO}(\text{C}_1\text{-C}_6\text{ alkyl})$ or halogen;

or R^2 and R^3 are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or $(\text{C}_1\text{-C}_6)\text{alkyl}$; and

R^4 is $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, $(\text{C}_2\text{-C}_{10})\text{alkenyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$, or $(\text{C}_3\text{-C}_{10})\text{heteroaryl}$, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from $(\text{C}_1\text{-C}_{10})\text{alkyl}$, $(\text{C}_2\text{-C}_{10})\text{alkenyl}$, $(\text{C}_2\text{-C}_{10})\text{alkynyl}$, $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, $(\text{C}_6\text{-C}_{10})\text{aryloxy}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, amino, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ alkyl})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkenyl})$, $\text{-NH}(\text{CO})(\text{C}_2\text{-C}_6\text{ alkynyl})$, $\text{-NH}(\text{CO})(\text{C}_1\text{-C}_6\text{ haloalkyl})$, halo, OCF_3 , CF_3 , hydroxyl, or a halogen radioisotope;

to form an incubation media;


b) incubating the incubation media of step a) under conditions sufficient to form an incubated mixture; and

c) analyzing the mixture of step b) by fluorescence microscopy, wherein an increase in the fluorescence signal of the mixture relative to the fluorescence signal of the compound of

Formula (I) not in the presence of a sample containing HSA is indicative of the presence of HSA.

13. The method of claim 12, wherein a measure of intensity of the fluorescence signal is proportional to the concentration of the HSA present in the sample.


14. The method of claim 12, wherein the compound of Formula (I) has the structure of formula (II):



or a pharmaceutically acceptable salt thereof.

15. A method for visualizing live neurons in a cell culture, comprising:

a) contacting a cell culture with the compound of claim 1 represented by Formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 is H or $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$, wherein $\text{CO}(\text{C}_1\text{-C}_6)\text{alkyl}$ is optionally substituted at any position with 1-3 substituents selected from halogen, hydroxyl, O-acetyl, NH-acetyl, or $-\text{NH}_2$;

R^2 and R^3 are each, independently, H, (C_1-C_{10}) alkyl, (C_6-C_{10}) aryl (C_0-C_6) alkyl, (C_3-C_{10}) heteroaryl, (C_3-C_8) cycloalkyl, (C_2-C_{10}) alkynyl or (C_2-C_{10}) alkenyl;

wherein (C_1-C_{10}) alkyl, (C_6-C_{10}) aryl (C_0-C_6) alkyl, (C_3-C_{10}) heteroaryl, (C_3-C_8) cycloalkyl, (C_2-C_{10}) alkynyl and (C_2-C_{10}) alkenyl are optionally substituted at any position with 1-5 substituents selected from (C_1-C_6) alkyl, (C_1-C_6) alkoxy, NH_2 , $-NH(C_1-C_6 \text{ alkyl})$, $-NH(CO)(C_1-C_6 \text{ alkyl})$, $-NH(CO)(C_1-C_6 \text{ haloalkyl})$, $-NH(CO)(C_1-C_6 \text{ alkoxy})$, $-NH(CO)(C_1-C_6 \text{ haloalkoxy})$, $-NH(CO)(C_2-C_6 \text{ alkenyl})$, $-Si(C_1-C_6 \text{ alkyl})$, $-SO_2(C_1-C_6 \text{ alkyl})$, $-SH$, $-B(OH)_2$, $-OTosyl$, $-CO(C_1-C_6 \text{ alkoxy})$, $-COH$, $-COOH$, $-CO(C_1-C_6 \text{ alkyl})$ or halogen;

or R^2 and R^3 are taken together to form a ring, wherein the ring is optionally substituted with 1-5 additional substituents selected from halogen or (C_1-C_6) alkyl; and


R^4 is (C_1-C_{10}) alkyl, (C_3-C_8) cycloalkyl, (C_6-C_{10}) aryl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, or (C_3-C_{10}) heteroaryl, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from (C_1-C_{10}) alkyl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, (C_3-C_8) cycloalkyl, (C_1-C_6) alkoxy, (C_6-C_{10}) aryloxy, (C_6-C_{10}) aryl, amino, $-NH(CO)(C_1-C_6 \text{ alkyl})$, $-NH(CO)(C_2-C_6 \text{ alkenyl})$, $-NH(CO)(C_2-C_6 \text{ alkynyl})$, $-NH(CO)(C_1-C_6 \text{ haloalkyl})$, halo, OCF_3 , CF_3 , hydroxyl, or a halogen radioisotope;

to form an incubation media;

b) incubating the incubation media of step a) under conditions sufficient to stain the live neurons; and

c) visualizing the stained live neurons of step b) with fluorescence microscopy.

16. The method of claim 15, wherein the compound of Formula (I) is a compound having the structure of Formula (XIV) or a pharmaceutically acceptable salt thereof:




wherein:

R^4 is (C_1-C_{10}) alkyl, (C_3-C_8) cycloalkyl, (C_6-C_{10}) aryl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, or (C_3-C_{10}) heteroaryl, further wherein R^4 is optionally substituted at any position with 1-5 substituents selected from (C_1-C_{10}) alkyl, (C_2-C_{10}) alkenyl, (C_2-C_{10}) alkynyl, (C_3-C_8) cycloalkyl, (C_1-C_6) alkoxy, (C_6-C_{10}) aryloxy, (C_6-C_{10}) aryl, amino, $-NH(CO)(C_1-C_6 \text{ alkyl})$, $-NH(CO)(C_2-C_6 \text{ alkenyl})$, $-NH(CO)(C_2-C_6 \text{ alkynyl})$, $-NH(CO)(C_1-C_6 \text{ haloalkyl})$, halo, OCF_3 , CF_3 , hydroxyl, or a halogen radioisotope; and


R^5 is present at any position with 1-5 substituents selected from H, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, NH_2 , $-NH(C_1-C_6 \text{ alkyl})$, $-NH(CO)(C_1-C_6 \text{ alkyl})$, $-NH(CO)(C_1-C_6 \text{ haloalkyl})$, $-NH(CO)(C_1-C_6 \text{ alkoxy})$, $-NH(CO)(C_1-C_6 \text{ haloalkoxy})$, $-NH(CO)(C_2-C_6 \text{ alkenyl})$, $-Si(C_1-C_6 \text{ alkyl})$, $-SO_2(C_1-C_6 \text{ alkyl})$, $-SH$, $-B(OH)_2$, $-OTosyl$, $-CO(C_1-C_6 \text{ alkoxy})$, $-COH$, $-COOH$, $-CO(C_1-C_6 \text{ alkyl})$ or halogen.

17. The method of claim 16, wherein the compound of Formula (I) has the structure of Formula (V):



or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1, having the structure of Formula (XVI):



or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1, wherein the halogen radioisotope is ¹⁸F.